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Background-—Cardiac hypertrophy increases the risk of developing heart failure and cardiovascular death. The neutrophil
inﬂammatory protein, lipocalin-2 (LCN2/NGAL), is elevated in certain forms of cardiac hypertrophy and acute heart failure. However, a
speciﬁc role for LCN2 in predisposition and etiology of hypertrophy and the relevant genetic determinants are unclear. Here, we
deﬁned the role of LCN2 in concentric cardiac hypertrophy in terms of pathophysiology, inﬂammatory expression networks, and
genomic determinants.
Methods and Results-—We used 3 experimental models: a polygenic model of cardiac hypertrophy and heart failure, a model of
intrauterine growth restriction and Lcn2-knockout mouse; cultured cardiomyocytes; and 2 human cohorts: 114 type 2 diabetes
mellitus patients and 2064 healthy subjects of the YFS (Young Finns Study). In hypertrophic heart rats, cardiac and circulating Lcn2
was signiﬁcantly overexpressed before, during, and after development of cardiac hypertrophy and heart failure. Lcn2 expression
was increased in hypertrophic hearts in a model of intrauterine growth restriction, whereas Lcn2-knockout mice had smaller
hearts. In cultured cardiomyocytes, Lcn2 activated molecular hypertrophic pathways and increased cell size, but reduced
proliferation and cell numbers. Increased LCN2 was associated with cardiac hypertrophy and diastolic dysfunction in diabetes
mellitus. In the YFS, LCN2 expression was associated with body mass index and cardiac mass and with levels of inﬂammatory
markers. The single-nucleotide polymorphism, rs13297295, located near LCN2 deﬁned a signiﬁcant cis-eQTL for LCN2 expression.
Conclusions-—Direct effects of LCN2 on cardiomyocyte size and number and the consistent associations in experimental and
human analyses reveal a central role for LCN2 in the ontogeny of cardiac hypertrophy and heart failure. ( J Am Heart Assoc.
2017;6:e005971. DOI: 10.1161/JAHA.117.005971.)
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C ardiac hypertrophy is, after age, the single mostimportant risk factor for cardiovascular death,1 often
as a result of heart failure. Hypertrophic remodeling of the
heart is usually in response to increased workload, and the
response to such stress has been shown to involve inﬂam-
matory pathways.2–4 Indeed, chronic inﬂammatory processes
have been implicated not only in response to stress, but also
more generally as primary etiological factors in cardiovascular
disease (CVD).5 Cardiovascular remodeling depends on
refashioning the interstitium, and inﬂammation stimulates
molecules, such as matrix metalloproteinase-9 (MMP9), that
degrade the interstitial matrix.6 MMP9 levels have been
associated with cardiovascular disease prognosis,7 and MMP9
is stimulated by the protein lipocalin-2 (LCN2), also known as
neutrophil gelatinase-associated lipocalin (NGAL).8,9 LCN2
levels have been used to reﬂect tissue damage, particularly of
the kidney, but more recently also for CVD manifestations,10
including hypertensive cardiac hypertrophy,11 coronary artery
disease12 and acute heart failure.13 LCN2 has also been
associated with long-term mortality following acute heart
failure, independent of renal function.14 However, it is unclear
whether LCN2 is simply a marker of an inﬂammatory process
or capable of direct effects on the heart that might contribute
to cardiac hypertrophy and failure.
In this study, we investigated the association of LCN2 with
concentric cardiac hypertrophy in genetic and environmental
experimental models and in relation to the normal variation of
human heart size and cardiac hypertrophy in diabetes
mellitus. We examined transcriptional associations with
LCN2 and identiﬁed genetic polymorphisms inﬂuencing
LCN2 expression. We determined the direct cellular effects
of LCN2 in cultured cardiomyocytes. Our ﬁndings reveal
increased LCN2 levels as a consistent association with
cardiac hypertrophy in a variety of models and human
cohorts, and our in vitro studies support a direct role for LCN2
in the origins of cardiomyocyte hypertrophy and reduced
cardiomyocyte proliferation.
Methods
Detailed methods are available in the Data S1.
Genetic Model of Cardiac Hypertrophy and Heart
Failure
The hypertrophic heart rat (HHR) is a normotensive inbred
polygenic model of adult cardiac hypertrophy, heart failure,
and premature death generated by us (Prof Stephen Harrap
and Prof Lea Delbridge, University of Melbourne, Melbourne,
Parkville, Australia).15 HHRs have a reduced endowment of
cardiomyocytes from very early life, a situation predisposing
to hypertrophy and failure in later life.15,16 Aged-matched
male animals were sampled during the following periods:
neonatal (postnatal day 2, n=11 HHR, n=10 Normal Heart Rat
[NHR]), adolescent (4 weeks old, n=4 HHR and n=4 NHR for
cardiomyocyte isolation), young adult (13 weeks old, n=7
HHR, n=7 NHR; 35 weeks old, n=8 NHR, n=11 HHR), and old
adult (50 weeks old, n=11 HHR, n=10 NHR).
Animals were euthanized by decapitation (neonatal) or with
an overdose of pentobarbitone (Lethobarb; adult animals). The
heart was immediately removed, and ventricles were dis-
sected from the atria. Cardiac weight index (mg/g) was
calculated from the total heart weight (mg) relative to total
body weight (g) of the animal. The studies involving animals
were approved by the Animal Ethics Committee of Deakin
University and the University of Melbourne and ratiﬁed at
Federation University Australia. They were performed accord-
ing to the “Code of Practice for the Care and Use of Animals
for Scientiﬁc Purposes” from the National Health & Medical
Research Council of Australia.
Rat Microarray Experiments
RNA was extracted from the left ventricle of 2-day-old HHRs
and NHRs (n=8/group, no pooling), and Affymetrix GeneChip
Rat Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA) was used
to assess genes differentially expressed with the assistance of
the Ramaciotti Centre for Gene Function Analysis. The data
set obtained has been deposited in the National Center for
Biotechnology Information Gene Expression Omnibus
Clinical Perspective
What is New?
• Using several animal models, in vitro and human studies, we
identiﬁed LCN2 as a central gene in the developmental
origins of cardiac hypertrophy leading to heart failure.
• Increased LCN2 expression has deﬁned effects of car-
diomyocyte proliferation and hypertrophy that might explain
cardiac hypertrophy and is likely to reﬂect chronic activation
of inﬂammatory pathways.
What are the Clinical Implications?
• The experimental effects of LCN2 on cultured cardiomy-
ocytes and in hearts of neonatal animals need to be
corroborated in clinical studies of relationships between
LCN2, heart size, and, if possible, cardiomyocyte numbers.
• LCN2 could be targeted as a therapeutic target and also
developed as an early marker for cardiac hypertrophy and
heart failure.
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database according to Minimum Information About a Microar-
ray Experiment guidelines with series accession number
GSE38607. Differentially expressed genes were identiﬁed
using a 2-sample t test in the Partek Genomics Suite (version
6.6; Partek Inc, Chesterﬁeld, MO), with Bonferroni-adjusted
P<0.05 and fold difference higher than 2.
Lcn2 mRNA and Protein Levels in Models of
Cardiac Hypertrophy and Heart Failure
Primers and conditions used for all real-time quantitative PCR
(qPCR) are shown in Table S1. Ampliﬁcation reactions used
the SensiFast SYBR Low-ROX Kit qPCR reagent system
(Bioline Reagents Ltd, London, UK) in a Viia7 qPCR instrument
(Life Technologies, Life Technologies, Carlsbad, CA). Immuno-
histochemistry was performed using an anti-LCN2 Rabbit
Polyclonal antibody (1:200 dilution, TA322583; OriGene
Technologies, Rockville, MD), followed by the EnVision+Sys-
tem-HRP. Western blots were performed as previously
described17 using anti-LCN2 Rabbit Polyclonal antibody or
b-actin (Cell Signaling Tecnology, Danvers, MA). Lcn2 plasma
and left ventricle (LV) protein levels were measured by ELISA
in duplicates in neonatal and adult HHR and NHR using the
Lipocalin-2 Rat ELISA Kit (Abcam, Cambridge, UK) according
to the supplier. Sanger sequencing was used to sequence
10 000 base pairs (bp) before and 2000 bp after the Lcn2
gene in the HHR and NHR (Table S1).
Lcn2-Knockout
Whole body and heart size of adult (12- to 13-week-old) Lcn2-
KO (n=6) and age-matched wild-type mice C57BL/6 (n=4),
generously donated by Prof Alan Aderem (Institute for
Systems Biology, University of Washington, Seattle, WA),
were measured upon death, and cardiac weight index was
calculated as described above.
Intrauterine Growth Restriction Rat Model
An environmental model of cardiac hypertrophy was devel-
oped using Wistar Kyoto rats by intrauterine growth restric-
tion, induced by uteroplacental insufﬁciency on day 18 of
pregnancy (term being 22 days), was also investigated.18,19
Six-month-old operated female and male rats (n=9) were
compared to Wistar Kyoto female and male sham rats (n=16).
In Vitro Experiments
The pExpress vector containing the cDNA for the rat Lcn2
(2 ng/mL, MRN1768-98079404; Thermo Fisher Scientiﬁc,
Waltham, MA) or empty vector (pExpress) were transfected
into rat embryonic ventricular myocardial cells (H9c2) using
Lipofectamine 2000 (Life Technologies). We counted the
number of cells by hemocytometry with the use of the
Countess Automated Cell Counter (Life Technologies). Wheat
germ agglutinin and Hoechst staining was used to measure
cell size,20 and phospho-histone H3 staining was used to
determine cell proliferation.20 Apoptosis was investigated by
ﬂow cytometry using an Annexin-V: FITC Apoptosis Detection
Kit I. All in vitro experiments were independently repeated 3
times, each time in triplicates.
RNA-Sequencing and Molecular Pathways
RNA was extracted from Lcn2-KO mice and cells transfected
with Lcn2 plasmid for 48 hours (and respective controls). RNA
from 3 samples of each group was sent to RNA-sequencing at
the Australian Genome Research Facility using the Illumina
HiSeq platform (v3 chemistry 100 bp paired-end sequencing).
Each sample was considered an individual sample and no
pooling was performed. Analysis of differential expression was
performed in the R statistical programming environment
(version 3.1.0) using Rsubread (version 1.14.2) and edgeR
(version 3.6.8) Bioconductor packages (Table S2).21 P values
were adjusted for multiple testing using the Benjamini-
Hochberg correction with a false discovery rate <0.05. Gene
ontology enrichment analysis was performed on ﬁltered lists
of differentially expressed genes to ask which pathways were
enriched in genes differentially expressed.
Human Echocardiography Measurements
Brieﬂy, 114 individuals with echocardiographic measures
were selected from a prospective cohort of type 2 diabetic
subjects22 whose basic characteristics are shown in Table S3.
In addition, subjects with echocardiographic measures from
the Young Finns Study (YFS) analyzed, shown in Table S4. The
YFS is a longitudinal population-based study of 3596 individ-
uals recruited during childhood in 1980.23 Genome-wide
genotype data, transcriptome-wide microarray proﬁling,
C-reactive protein (CRP), glycoprotein acetylation (GlycA),
and echocardiographic measurements were available for
different subsets of 2064 individuals aged 34 to 48 years,
participating in the 2011 follow-up study.24–27 The cohort
studies complied with the Declaration of Helsinki and were
approved by the human ethics committee at each institution.
All subjects gave informed consent.
In both cohorts, echocardiographic examinations were
performed using transthoracic echocardiography by an Acu-
son Sequoia 512 (Acuson, Mountain View, CA) with a 3.5-MHz
scanning frequency phased-array transducer. From the ultra-
sound images, LV structure, systolic, and diastolic function
were measured following the guidelines of the American
Society of Echocardiography, as previously described.28,29
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Cardiac hypertrophy was deﬁned as LV mass indexed to the
body surface of >95 g/m2 in women and >115 g/m2 in
men.30 E/E0-ratio was calculated using the average values of
lateral and septal e0 velocity.29
Human Plasma LCN2 Measurement
Human plasma was used to measure LCN2 levels in
duplicates in 121 subjects with type 2 diabetes mellitus
using the Quantikine ELISA Human Lipocalin-2 Immunoassay
(R&D Systems, Minneapolis, MN), according to the supplier.
LCN2 mRNA Levels in Human Heart
We used data in the repository Gene Expression Omnibus
series GSE1145 to investigate the levels of LCN2 in human
idiopathic dilated hearts (n=11 control hearts and n=15
idiopathic dilated hearts). We performed a whole-genome
analysis using the Gene Expression Omnibus tools, including
false discovery rate <0.05, to determine whether LCN2 was
overexpressed in human idiopathic dilated hearts.
GlycA Measurement
GlycA reﬂects the integrated concentrations and glycosylation
states of several of the most abundant inﬂammatory acute-
phase glycoproteins31,32 measured with a proton nuclear
magnetic resonance metabolomics platform.33
CRP Measurement
High-sensitivity CRP was quantiﬁed from serum samples
using an automated analyzer with a latex turbidimetric
immunoassay kit.
Coexpression Networks and Quantitative Trait
Loci
Transcriptome-wide microarray proﬁling was performed on
whole blood for 1650 individuals in the YFS as previously
described.24 Brieﬂy, stabilized total RNA was obtained from
whole blood for individuals in the YFS. RNA was hybridized to
Illumina HT-12 (version 4; Illumina, San Diego, CA) BeadChip
arrays, and raw probe data were exported with the Illumina
BeadStudio software. Both positive and negative control
probes were used to quantile normalize using the limma R
package.34 Probe intensities were reported on a log2 scale.
Identiﬁcation and characterization of the gene coexpression
network analyzed in this study is described in Ritchie et al.32
Here, we deﬁned the neutrophil module’s coexpression as the
Spearman’s correlation coefﬁcient between its 27 genes.32
The average expression was used for genes with multiple
microarray probes. Edges in the coexpression network were
deﬁned as the magnitude of the correlation exponentiated to
the power of 4. A vector summarizing module expression was
calculated for association testing as the ﬁrst eigenvector of a
principal components analysis on module expression. This
summary expression proﬁle captured 57% of the total variation
in module gene expression. Association analyses are described
in the Statistical Analyses section below.
Genome-wide genotyping was carried out on whole-blood
samples for 2442 individuals participating in the 2001 follow-
up study of the YFS as previously described.25 Sample and
genotype quality control was performed for these 2442
individuals (Data S1). A combined total of 6 721 082 directly
genotyped and imputed single-nucleotide polymorphisms
(SNPs) passed quality control.
Module quantitative trait loci (QTLs) were identiﬁed for 1386
individuals with matched genotype and gene expression data in
the YFS through a genome-wide scan for SNPs associated with
the summary expression proﬁle using PLINK 1.90 beta (version
3.32). Individual associations were tested using a linear model
of minor allele dosage on neutrophil module summary expres-
sion. An SNP was considered a module QTL where P<59108
(genome-wide signiﬁcance). Models were adjusted for age, sex,
and the ﬁrst 2 principal components of the genotype data. The
module QTL, rs13297295, on chromosome 9 was further
tested for an association with LCN2 expression levels using the
same model. Rs13297295 was also tested for association with
GlycA and CRP in the 1712 individuals with matched genotype
and GlycA or CRP data.
Statistical Analyses
R software (version 3.13; R Foundation for Statistical Com-
puting, Vienna, Austria) was used for the analyses of the YFS
data. The NetRep package (version 0.54) was used for network
analyses.35 Measurements of GlycA, routine lipids, CRP, body
mass index (BMI), heart function (measured as early ﬁlling [E]
to early diastolic mitral annular velocity [E0]—E/E0 ratio, and E
to late [A] diastolic ﬁlling—E/A ratio) were normalized using a
natural logarithm transformation, and all continuous measure-
ments were standardized to SD units in both cohorts. Module
associations with the inﬂammatory biomarkers were assessed
by linear regression of: neutrophil module expression on GlycA
and CRP; linear regression of LCN2 expression on GlycA and
CRP. To assess whether LCN2 was a mediator of the
relationship between these biomarkers and the neutrophil
module, we used linear regression of: GlycA and CRP on LCN2
expression and neutrophil module expression; CRP on LCN2
expression and neutrophil module expression; and GlycA on
LCN2 expression and neutrophil module expression. All terms
in the models were additive, and all models were adjusted for
age and sex. Matched gene expression, GlycA, and CRP data
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were available for 1650 individuals. Associations between
LCN2 expression and echocardiographic measurements in the
YFS (Table S5) were tested by linear regression of each
echocardiographic measurement on LCN2 expression, adjust-
ing for age and sex. Each association was considered
signiﬁcant where P<0.05. Matched gene expression and
echocardiographic data were available for between 1482 and
1573 individuals depending on the LV phenotype.
Inter- and intraassay coefﬁcients of variability were calcu-
lated for ELISAs, and only less than 15% variability was
accepted (hence 7 human samples from the type 2 diabetes
mellitus cohort were excluded from further analyses). Human
plasma LCN2 levels were not normally distributed; therefore,
LCN2 was log transformed for the association analyses
presented in Table S3. An independent t test was used to
assess differences in continuous variables between those
with and without cardiac hypertrophy or chi-square analyses
for dichotomous variables. A general linear model analysis
was performed to test for associations between presence of
cardiac hypertrophy and plasma LCN2 levels after adjusting
for variables from the univariable analysis with a P value of
<1.0 (age, sex, BMI, estimated glomerular ﬁltration rate, and
systolic blood pressure). We used untransformed LCN2 levels
to perform Spearman Rho correlations between human
plasma LCN2 and LV left ventricle mass and function in the
type 2 diabetes mellitus cohort (Table S6). Signiﬁcance was
set at P<0.05.
Results from the animal groups were tested for normal
distribution using the Skewness and Kurtosis tests. Indepen-
dent sample t tests (with Welch’s correction in the case of
different variance) and ANOVA were used to compare the data
between the animal groups. A 2-way ANOVA was used to
compare between Lcn2 expression in the different cell types
in HHRs and NHRs.
Results
Lcn2 Is Associated With Cardiac Size in
Experimental Genetic and Environmental Models
HHR and NHR
A transcriptome analysis of neonatal P2 LV tissue identiﬁed 21
geneswith signiﬁcant differential expression betweenHHRs and
NHRs (Table S7 and Figure S1) involving pathways for cardio-
vascular system development and function, and cell growth and
proliferation (Tables S8 and S9), with Lcn2 showing the greatest
differential expression (q=791011; Table S7). Elevated cardiac
Lcn2 expression was validated by qPCR at postnatal day 2
(Figure 1A) and was found to persist with established hypertro-
phy at 13 weeks of age and with the emergence of heart failure
at 35 or 50 weeks of age (Figure 1B) and further conﬁrmed by
25-kDa Lcn2 monomer protein analyses (Figure 1C and 1D).
Comparedwith its control strain, theNHR,we found signiﬁcantly
higher circulating Lcn2 in adult HHRs with established hyper-
trophy at 35 weeks of age (Figure 1E), but also soon after birth
(Figure 1F) before hypertrophy is evident but cardiomyocyte
numbers are already reduced. RNA and immunohistochemical
studies (Figure 1G and 1H) showed Lcn2 expression in
cardiomyocytes and noncardiomyocyte (ﬁbroendothelial) cells.
Correlation between cardiac Lcn2mRNA and plasma Lcn2 in the
HHRs and NHRs was r=0.996 (P<0.001).
Sequencing the HHR and NHR Lcn2 genes for comparison
with the published sequence for spontaneously hypertensive
rats and Fisher 344 (original progenitors of HHR and NHR), we
found 3 unique SNPs in the HHR, all inherited from the
spontaneously hypertensive rats, with 1 being intronic and 2
being upstream of the coding sequence (Figure 2A through
2D). In the HHR heart, both Lcn2 mRNA and pre-mRNA levels
were increased (Figure 2E), suggesting a transcriptional
dysregulation of Lcn2 in the HHR. Transcription Factor Afﬁnity
Prediction (sTRAP)36,37 analysis suggested that one of these
SNPs (rs196968512) created a binding site for the enhancer,
RAR-related orphan receptor A (Figure 2B and 2F).38
Lcn2 knockout mice
Hearts from adult mice with double knockout of the Lcn2 gene
(Lcn2-KO)39 were signiﬁcantly smaller than age-matched wild-
type mice (cardiac weight index 5.4 versus 5.9 mg/g; P=0.03;
Figure 3A). RNA-sequencing ofmurine heart tissue from Lcn2-KO
versuswild-type identiﬁed16signiﬁcantly differentially expressed
genes (Table S10) that are relevant to pathways related to
hypertrophic cardiomyopathies (Table S11; Figure 3B and 3C).
Intrauterine growth restricted rats
Last, in an environmental model of intrauterine growth
restriction,18,19 we demonstrated that subsequent adult
cardiac hypertrophy was associated with signiﬁcantly higher
levels of cardiac Lcn2 mRNA (P=0.0214; Figure 4).
Lcn2 Overexpression Induces Hypertrophy in
Cardiomyocytes and reduces proliferation
We next sought to determine whether increased Lcn2
transcription in cardiomyocytes results in a hypertrophic
phenotype. We transfected rat embryonic ventricular myocar-
dial cells with a plasmid containing the Lcn2 mRNA sequence
and performed imaging and RNA-sequencing analyses. Sig-
niﬁcant increase in the expression of Lcn2 in transfected cells
(log fold change=4.44; q=0.0005; Figure S2) resulted in a
signiﬁcant increase in the size of transfected cells (Figure 5A
and Figure S3A). In these hypertrophic cells, we found
signiﬁcantly increased expression of 2 genes previously linked
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with hypertrophic cardiomyopathy—thrombospondin 2 (log
fold change=0.36; q=0.0005) and dynamin 1 (log fold
change=0.48; q=0.044).40,41 In addition to hypertrophy,
overexpression of Lcn2 resulted in a signiﬁcant decrease in
cell numbers (Figure 5B) with a concomitant reduction in cells
positive for phosphorylated histone H3, reﬂecting reduced cell
mitosis (Figure 5C and Figure S3B). No change in apoptosis
was observed (Figure S4). Pathway enrichment analysis of the
529 genes with nominally signiﬁcant evidence of differential
expression (unadjusted P<0.05) between transfected and
control myocytes suggested dysregulation of genes related to
cell cycle (Kyoto Encyclopedia of Genes and Genomes
rno04110; P=0.006). There was suggestive evidence for
genes related to hypertrophic cardiomyopathy (Kyoto
Encyclopedia of Genes and Genomes rno05410; P=0.07)
and dilated cardiomyopathy (Kyoto Encyclopedia of Genes
and Genomes rno05414; P=0.09; Figure 5D and 5E;
Table S12).
Human LCN2 Is Associated With LV Hypertrophy
in Diabetes Mellitus
Obesity and type 2 diabetes mellitus have been associated
with elevated levels of plasma LCN2.42,43 Independently from
those ﬁndings, cardiac hypertrophy has been associated with
diastolic dysfunction and is recognized as a diabetic compli-
cation.44 However, whether cardiac hypertrophy and diastolic
dysfunction in type 2 diabetic patients is associated with high
Figure 1. Overexpression of lipocalin-2 (Lcn2) in a polygenic model of cardiac hypertrophy. A, Relative expression levels of Lcn2 mRNA
measured by real-time PCR in the heart of 2-day-old hypertrophic heart rat (HHR; n=10) compared to normal heart rat (NHR; n=8; P<0.0001), (B)
13-week-old (P=0.016; n=9/strain), 35-week-old (P<0.001; n=8 NHR and n=11 HHR), and 50-week old (P=0.0015; n=8 NHR and n=11 HHR)
HHR compared to NHR. Heart Lcn2 (25-kDa monomer) protein is signiﬁcantly higher in the HHR compared with NHR, measured by both (C)
western blot (P=0.039; n=3/strain) and (D) ELISA (P=0.029; n=4/strain). E, Rat plasma Lcn2 in 35-week-old (P=0.0009; n=6/strain) and (F)
2-day-old (P<0.0001; n=5/strain) HHR compared to NHR. G, Lcn2 mRNA in cardiomyocytes (P=0.013; n=4/strain) and noncardiomyocytes
(P=0.03) in the NHR and HHR. The interaction explained 5.135% of total variation (P=0.138), the cell type 6.91% of variation (P=0.0899), and the
strain explained the majority of variation (63.58%; P=0.0001). H, Lcn2 staining in NHR and HHR hearts (9400 magniﬁcation; scale bar=200lm).
*P<0.05; **P<0.01; ***P<0.001. Data shown as mean and error bars represent SEM.
DOI: 10.1161/JAHA.117.005971 Journal of the American Heart Association 6
Lcn2 in Cardiac Hypertrophy Marques et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
LCN2 levels is not known. Echocardiographic assessment of
114 patients with type 2 diabetes mellitus and normal renal
function revealed signiﬁcantly higher levels of mean plasma
LCN2 in the 30 diabetic subjects with LV hypertrophy than
those 84 without 44.0 ng/mL [95% CI, 38.350.6] versus
36.0 ng/mL [33.139.2] P=0.017) that remained after
adjustment for age, sex, BMI, estimated glomerular ﬁltration
rate, and systolic blood pressure (P=0.034; Figure 6A). There
Figure 2. Variants in the lipocalin-2 (Lcn2) gene, showing regions with variants in the HHR, according
to the Rat Genome Database (RGD; version 5). A, Genotype analysis of the region of 10 000 bp around
the Lcn2 gene, showing the origin of the variants observed in the HHR. Highlighted in gray are variants
that differ from the reference genome, showing that the HHR carries 3 unique variants which were
inherited from the SHR. B, Single-nucleotide polymorphism (SNP) on chr3: 16 767 791 (rs196968512
C/T) 1401 bp upstream of Lcn2 gene. C, SNP on chr3: 16 767 398 (G/A) in a highly conserved region
1001 bp upstream the Lcn2 gene. D, Nonfunctional intronic SNP originally from SHR on position chr3:
16 763 494 (rs198262931 C/T). E, Lcn2 pre-mRNA is also upregulated in the HHR compared to the
NHR (n=5/strain), suggesting that it is dysregulated at the transcriptional level. F, The SNP,
rs196968512, creates a new binding site for the transcription factor, Rora (region underlined in B),
which acts as an enhancer for expression of Lcn2 and is exclusive of the HHR. The ﬁgure shows the
binding site score and the P values for the binding of Rora to that region. chr3 indicates rat
chromosome 3; F344, Fisher 344 rat; HHR, hypertrophic heart rat; N/A, nonannotated SNP; NHR,
normal heart rat; RGD, reference sequence from the Rat Genome Database v5; SHR, spontaneously
hypertensive rat.
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was a positive correlation between LCN2 levels and LV mass
(n=114; Spearman’s r=0.22; P=0.018; Figure 6B and
Table S6). In diabetic subjects with cardiac hypertrophy,
there was evidence of diastolic dysfunction (Table S3) with a
signiﬁcantly increased E/E0 ratio (meanSD 15.24.5 versus
11.43.5; P<0.0001), but there was no association between
these measurements and LCN2 (Table S6).
LCN2 mRNA Is the Human Heart
From subjects with idiopathic dilated cardiomyopathy, cardiac
RNA expression data in a public repository (GSE1145)
revealed overexpression of cardiac LCN2 after adjustment
for multiple comparisons (Figure 6C; false discovery rate,
q=0.008).
LCN2 Expression, Cardiac Size and Function, and
BMI in the YFS
In the 1590 YFS individuals (mean age, 42 years) with matched
echocardiographic and whole-blood gene expression data,
linear regression analysis adjusted for age and sex showed that
LCN2 expression was associated with various structural and
functional LV phenotypes (Table S5). Higher LCN2 expression
was associated with increased heart rate (P=69106), LV end-
diastolic volume (P=0.02), and cardiac output (P=39106). LV
mass (P=59105) and thickness of the interventricular septum
(P=89104) were also positively correlated with LCN2
expression. Although the negative correlation between
LCN2 expression and E/A ratio (P=59104) suggested
diastolic impairment, this might have been confounded by
the increased heart rate,45 given that other measures of
diastolic function (E/E0 ratio, mitral E-wave declaration time,
and isovolumic relaxation time) did not show signiﬁcant
A
c
B
Figure 3. Heart size and associated pathways in lipocalin-2 (Lcn2)-knockout (KO) mice. A, Adult Lcn2-knockout mice have
smaller hearts (*P=0.033; n=4 wild-type and n=6 Lcn2 KO). Data shown as mean and error bars represent standard error
of mean. B, Genes and pathways differentially regulated in the heart of Lcn2-knockout. Hypertrophic cardiomyopathy
(KEGG mmu05410, P=0.0007) is shown in red, dilated cardiomyopathy in blue (Kyoto Encyclopedia of Genes and Genomes
[KEGG] mmu05412; P=0.008) and arrhythmogenic right ventricular cardiomyopathy in yellow (KEGG mmu05412;
P=0.0003). The genes of dilated cardiomyopathy and hypertrophic cardiomyopathy pathways were the same, and
therefore lines are overlapped. Each edge point indicates the chromosomal location for genes identiﬁed in speciﬁc
pathways from the differentially expressed genes. Bar plots are the differentially expressed genes in each pathway. Red
depicts genes upregulated, and blue those downregulated, represented as log2 fold change. C, Gene ontology analysis,
showing log P value. ABC indicates ATP-binding cassette; ECM extracellular matrix.
Figure 4. Environmental model of cardiac hyper-
trophy overexpresses lipocalin-2 (Lcn2) mRNA
(*P=0.0214; n=16 sham and 9 restrictedmice). Data
shown as mean and error bars represent SEM.
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correlations with LCN2 expression (Table S5). There was also
no signiﬁcant correlation between LCN2 expression and
indices of systolic function, including ejection fraction and
systolic wall velocities (Table S5). In addition, LCN2 expres-
sion correlated signiﬁcantly with BMI (r=0.33; 95% CI, 0.28–
0.37; P=891042). In terms of LV phenotypes, BMI was
associated with increased LV size, heart rate, end-diastolic
volume, and cardiac output (data not shown). There was also
more consistent evidence of reduced diastolic function with
increasing BMI, although systolic function was normal.
Regression models that included LCN2 expression and BMI
revealed that the correlation between BMI and LCN2
expression could account for the associations observed for
LCN2 expression alone (data not shown). This has been
reported previously and interpreted as part of the low-grade
inﬂammatory activation that accompanies obesity and pre-
disposes to insulin resistance and type 2 diabetes mellitus.42
LCN2 Is Central to a Neutrophil Gene
Coexpression Network and Is Under Genetic
Control
Previous analysis of whole-blood gene expression data
identiﬁed a reproducible tightly coexpressed gene module
A
E
B
D
C
Figure 5. Role of lipocalin-2 (Lcn2) in cardiac cells. A, Representation of wheat-germ agglutinin (red) and DAPI (blue) staining, used to estimate
cell size (9400 magniﬁcation; scale bar=60 lm). Overexpression of Lcn2 increased the size of the cells when compared with cells transfected
with the empty plasmid (P<0.0001). B, Overexpression of Lcn2 reduced the number of cells measured by hemocytometer (P=0.0052). C,
Overexpression of Lcn2 resulted in cell-cycle arrest, observed by reduced phosphorylation of histone H3 (pH3; 9200 magniﬁcation; scale
bar=100 lm; P<0.0001). D, Genes and pathways differentially regulated with overexpression of Lcn2. Cell cycle (Kyoto Encyclopedia of Genes
and Genomes [KEGG] rno04110; P=0.006) is shown in green, hypertrophic cardiomyopathy (KEGG rno05410, P=0.07) in red, and dilated
cardiomyopathy (KEGG rno05414; P=0.09) in blue. Genes of dilated cardiomyopathy and hypertrophic cardiomyopathy pathways were the same,
and therefore lines overlapped. Each edge point indicates the chromosomal location for genes identiﬁed in speciﬁc pathways from the
differentially expressed genes. Bar plots are the differentially expressed genes in each pathway. Red depicts genes upregulated, and blue those
downregulated, represented as log2 fold change. E, Gene ontology analysis, showing log P value. All experiments were run in 3 independent
experiments, with at least 3 replicates each (total, 9 replicates). For experiments involving confocal microscopy, 10 different ﬁelds were
analyzed per replicate. Positive controls were added to all experiments. **P<0.01; ***P<0.001. Data shown as mean and error bars represent
SEM.
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associated with elevated levels of inﬂammatory markers in 2
independent healthy population studies.32 This module was
signiﬁcantly enriched for genes involved in the innate
immune response, in particular neutrophil function.32 Among
these, the expression of LCN2 showed high centrality to the
neutrophil module (Figure 7), with a scaled connectivity
(Data S1) of 0.65 and a correlation of 0.89 with the
module’s summary expression proﬁle. In a healthy popula-
tion of 1650 individuals from the YFS cohort (Table S4), we
found that the module summary expression was indepen-
dently associated with both GlycA (b=0.16; 95% CI, 0.11–
0.21; P=29109) and CRP (b=0.15; 95% CI, 0.093–0.20;
P=59108) when both were included in the same model,
suggesting the module is related to inﬂammatory processes
reﬂected by both biomarkers. Although LCN2 expression
itself was independently associated with both GlycA
(b=0.18; 95% CI, 0.12–0.23; P=791011) and CRP
(b=0.19; 95% CI, 0.14–0.24; P=391012), GlycA and CRP
were no longer signiﬁcant when LCN2 was included in the
model. This suggests that LCN2 on its own is a better
predictor of the module summary proﬁle. To determine the
potential genetic determinants of the neutrophil module
function, we performed a QTL scan on the neutrophil
module’s summary expression (Data S1) in 1650 healthy
individuals from the YFS cohort. We found that rs13297295,
the top module QTL, was located 750 kb downstream from
LCN2 to which it was a cis-eQTL, with each “C” allele at
rs13297295 increasing expression of LCN2 by 0.39 SD
(P=29109; adjusted for age, sex, and 2 genetic principal
components). There was no detectable association between
rs13297295 and CRP or GlycA. Taken together, these
results suggest that increased LCN2 expression is central to
the inﬂammatory gene module.
Discussion
Our experimental and human studies reveal increased levels of
LCN2 as a consistent correlate of cardiac hypertrophy (sum-
marized in Figure 8). This relationship existed in the HHR
polygenic model of spontaneous cardiac hypertrophy leading to
heart failure, in Lcn2 gene knockout mice, but also in an
environmental model of cardiac hypertrophy following
intrauterine growth retardation. In human studies, LCN2 was
associated with cardiac hypertrophy in healthy subjects of the
YFS and in patients with type 2 diabetes mellitus. Importantly,
our in vitro studies of Lcn2 overexpression showed that it can
activate hypertrophic pathways and cause an increase in
cardiomyocyte size but a decrease in their proliferation.
Irrespective of the primary cause of increased LCN2, these
direct cellular effects provide a common fundamental patho-
physiology for the contribution of LCN2 to cardiac hypertrophy.
This is the ﬁrst time that a speciﬁc cardiomyocyte
hypertrophic effect of LCN2 has been demonstrated. Previous
studies have focused on the effects of LCN2 on the interstitial
matrix through induction of the proteinase, MMP9. This is
relevant to the degradation of intercellular matrix as part of
the remodeling of the heart during the development of
hypertrophy. However, we could ﬁnd no signiﬁcant variation in
MMP9 expression in association with changes in Lcn2 in HHR
and Lcn2 knockout mice (data not shown). It would also be
beneﬁcial to submit Lcn2 knockout mice to stressors such as
transverse aortic constriction to further understand the role of
Lcn2 in heart disease, but this was outside the scope of this
study.
Interestingly, we observed that Lcn2 expression reduced
in vitro cardiomyocyte proliferation and cell numbers. It might
seem counterintuitive that a limitation of cardiomyocyte
Figure 6. Lipocalin-2 (LCN2) is associated with human cardiac hypertrophy. A, Plasma levels of LCN2 were higher in patients with
echocardiographically determined left ventricular hypertrophy (n=30) compared with those without (n=84; P=0.017, showing the median and
95% CI). B, There was a positive correlation between LCN2 levels and left ventricular mass (n=114; Spearman’s r=0.22; P=0.018). C, LCN2 was
overexpressed in human idiopathic dilated hearts compared with normal hearts (P=0.008 after adjustment for false discovery rate). Data shown
as mean and error bars represent SEM. *P<0.05; **P<0.01.
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numbers would contribute to cardiac hypertrophy. However,
in very early life, when cardiomyocyte replication establishes
the endowment of cardiac contractile cells, the actions of
Lcn2 to reduce cell numbers could have long-lasting effects.46
Fewer cells means greater individual workload resulting in
hypertrophy. We have shown previously that the HHR has a
reduced complement of cardiomyocytes in early postnatal life,
an age at which we discovered cardiac Lcn2 to be highly
expressed. Although we have no measurements of cardiomy-
ocyte numbers in the early postnatal period following
intrauterine growth restriction, other studies have shown that
birth weight is associated with reduced numbers of cardiomy-
ocytes,47 and very early protein restriction has been associ-
ated with increased cardiomyocyte apoptosis.48 Therefore,
increased Lcn2 very early in life (whether genetic or
environmental in origin) could predispose to hypertrophy
through effects on cell number. The propensity for hypertro-
phy would be magniﬁed by any persistent increase in Lcn2
levels into adulthood, as we saw in the HHR and in adult
animals that had experienced intrauterine growth retardation.
In our human analyses, we found that LCN2 expression
correlated signiﬁcantly with cardiac size in healthy subjects in
the YFS. Cardiac size also correlated with BMI in these
subjects. Increased BMI is known to augment LCN2, probably
as part of the induction of a chronic mild inﬂammatory
state.49 Given the direct effects of LCN2 on cardiomyocyte
hypertrophy, it is not unreasonable to suggest that at least
part of the inﬂuence of BMI on heart size might be mediated
through increases in LCN2. Diabetes mellitus is also charac-
terized as a state of chronic inﬂammation and cardiac
hypertrophy is a common ﬁnding patients with type 2
diabetes mellitus.50 We found that diabetic patients with
cardiac hypertrophy had signiﬁcantly higher plasma concen-
trations of LCN2, even after adjustment of BMI, renal function,
and blood pressure. In the absence of other measures of
inﬂammatory markers, we cannot be certain of the explana-
tion of the elevated LCN2 in those diabetics with cardiac
hypertrophy.
The factors that might increase LCN2 deserve considera-
tion. LCN2 exhibits complex and tissue-speciﬁc regulation and
pathophysiology relevant to a broad portfolio of biological
functions and disease involvements, including bacterial
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Figure 7. Neutrophil module: An inﬂammatory biomarker asso-
ciated coexpression network is under genetic control of a cis-
eQTL of lipocalin-2 (LCN2). A, coexpression heatmap (Spearman’s
correlation) and scaled network connectivity (Methods) of genes
composing the neutrophil module in the YFS (n=1650). B,
Box plots of age- and sex-adjusted LCN2 expression in individuals
with differing dosages of the rs13297295 minor allele (“C”). C,
Locus zoom plot of the 1-MB region around LCN2 showing
association on the y-axis (log10 P value) between each single-
nucleotide polymorphism (points) and LCN2 expression, recom-
bination rate in the EUR population in that region (blue line
underneath the points), and r2 between each SNP and
rs13297295 (point color).
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infection, inﬂammation, cancer, renal damage, obesity, and,
more recently, CVD.51
In the YFS, the associations between LCN2 and the
biomarkers, CRP and GlycA, suggest that underlying activation
of inﬂammatory pathways might be responsible. LCN2 is
released from neutrophils in response to inﬂammatory
cytokines, including tumor necrosis factor-a, interleukin-1b
and interleukin-6.51 We analyzed the transcriptional subnet-
works associated with the biomarkers of low-grade inﬂam-
mation in otherwise healthy individuals of the YFS. LCN2
expression appeared central to a coexpression module
representing proteins secreted or expressed by neutrophils
as part of the innate immune response.32 The expression of
this neutrophil module was signiﬁcantly associated with levels
of both CRP and GlycA. Expression QTL analyses identiﬁed a
common human genetic variant that increased LCN2 levels
(rs13297295 “C” allele) and was also positively associated
with module expression. Despite limited power to detect
hypertrophic phenotype associations, further studies of this
LCN2 eQTL in human cardiomyocytes is warranted.
In relation to increased Lcn2 expression in the HHR,
evidence of underlying activation of inﬂammatory pathways is
less clear. We could ﬁnd no signiﬁcant differential cardiac
expression in neonatal HHR of the cytokines, tumor necrosis
factor-a, interleukin-1b, or interleukin-6, or the acute-phase
reactants that comprise the majority of GlycA (data not
shown). Nor was there any signiﬁcant association of Lcn2
with MMP9 expression. Given the polygenic nature of the
HHR, other genetic factors are presumed to drive the higher
Lcn2 expression. In a simple candidate gene approach, we
identiﬁed 3 differences in DNA sequence in and around the
Lcn2 gene between HHR and NHR, 1 of which (rs196968512)
created a binding site for the transcriptional enhancer, RAR-
related orphan receptor A. The signiﬁcance of this SNP and
other polymorphisms requires further investigation in cross-
breeding linkage analyses.
The downstream effects of Lcn2 on cardiac expression
pathways were reasonably consistent with changes in the
pathways typically associated with hypertrophy observed in
the HHR, the Lcn2 knockout mice, and in cultured cardiomy-
ocytes. Of particular interest, in vitro Lcn2 overexpression
downregulated the genes for dynamin 1 and thrombospondin
2 in cardiomyocytes. Mice with a mutation in the gene for
dynamin 1 develop dilated cardiomyopathy through mito-
chondria defect and thus energy deﬁciency in the heart.40
thrombospondin 2-knockout mice also display dilated car-
diomyopathy with progressive cardiomyocyte stress and
death.41
Our ﬁndings add to the evidence supporting a role for
LCN2 in CVD, likely through inﬂammatory processes. Previous
studies have shown LCN2 to be associated with atheroscle-
rosis and plaque instability, endothelial dysfunction, oxidative
stress,52 interstitial ﬁbrosis,53 myocarditis, cardiac remodel-
ing, and heart failure.54,55 Baseline circulating LCN2 levels
↑ LCN2
SNP rs13297295 
↑Cardiac hypertrophy and ↓ function
↑Cardiomyocyte size
↓Cardiomyocyte proliferation
Figure 8. Diagram showing summary of ﬁndings. LCN2 indicates lipocalin-2; SNP, single-nucleotide
polymorphism.
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have been independently associated with subsequent devel-
opment of CVD in 1 population study56 and in a 4-year follow-
up after cerebrovascular ischemia study.57
Perspectives
The actions of LCN2 that we have observed on cardiomyocyte
division and growth have implications for the development of
cardiac hypertrophy and failure. The timing of the actions of
LCN2 is also important. In the perinatal period, LCN2 could
reduce the endowment of cardiomyocytes. In adulthood, LCN2
would tend to augment cardiomyocyte hypertrophy in
response to any form of myocardial injury. The stimuli to
LCN2 expression are both genetic—as in the HHR polygenic
model in rats and possibly in the case of rs13297295 in man—
and also environmental, as in the case of early-life deprivation
or other inﬂammatory activators, such as obesity and type 2
diabetes mellitus. Unfortunately, there are no human data
regarding LCN2 in the neonatal period, and it is yet to be
determined whether adult human cardiac hypertrophy might
have its origin in reduced numbers of cardiomyocytes, but this
emerges as a fascinating and important possibility.
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Animal Samples 
We then studied the hypertrophic heart rat (HHR) as a normotensive inbred polygenetic 
model of adult cardiac hypertrophy and failure that begins life with a smaller heart and fewer 
cells1, 2. Neonatal male (day 2, n=11 HHR, n=10 NHR), adolescent (4-week old, n=4 HHR 
and n=4 NHR for cardiomyocyte isolation), young adult (13 weeks-old, n=7 HHR, n=7 
NHR) and old adult (50 weeks-old, n=11 HHR, n=10 NHR) age-matched animals were 
euthanized by decapitation (neonatal) or with an overdose of pentobarbitone (Lethobarb) 
(adult animals). The heart was immediately removed, and the ventricles were dissected from 
the atriums. Cardiac weight index (CWI, mg/g) was calculated from the total heart weight 
(mg) relative to total body weight (g) of the animal. HHR samples presented hypertrophy 
since 4 weeks of age (data not shown). Plasma was also collected. An environmental model 
of left ventricular hypertrophy developed using Wistar Kyoto (WKY) rats by intra-uterine 
growth restriction induced by uteroplacental insufficiency on day 18 of pregnancy (term=22 
days) was also investigated 3, 4. Six month old male operated animals (n=3) were compared to 
WKY sham rats (n=7). For all samples, the tissues used were first preserved in liquid 
nitrogen and later transferred to a –80oC freezer, and RNA was extracted using miRNeasy kit 
(Qiagen). Based on the means and standard deviation reported in the manuscript, the number 
of samples used resulted in power >95% for both t-test and analysis of variance (ANOVA), 
as calculated using the software G*Power version 3.0.10 (http://www.gpower.hhu.de). The 
study was approved by the Animal Ethics Committee of the University of Melbourne and 
Deakin University, and ratified at Federation University Australia.  
Microarray Experiments and Analyses 
Total RNA was extracted from left ventricle of neonatal HHR (4 male, 4 female) and NHR (4 
male, 4 female) using the miRNeasy Mini kit (Qiagen). Affymetrix GeneChip® Rat Gene 1.0 
ST Arrays were used for transcriptome-wide gene expression analysis. Each animal was 
considered an individual sample and no pooling was performed. Briefly, mRNA was 
converted to ssDNA, labelled and hybridized to GeneChip® Rat Gene 1.0 ST Arrays, which 
analyse 27,342 gene transcripts using 722,254 probe sets (on average 26 probes per gene), 
according to the manufacturer’s instructions, and with the assistance of the Ramaciotti Centre 
for Gene Function Analysis (University of New South Wales, Sydney, Australia). The data 
set obtained has been deposited in the NCBI Gene Expression Omnibus (GEO) database 
according to MIAMI guidelines with series accession number GSE38607 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bjsxbiiaowmwozy&acc=GSE38607). 
Results from arrays were normalized using robust-multi-array analysis (RMA). 
Differentially expressed genes were identified using a two-sample t-test in the 
Partek® Genomics Suite™ (version 6.6). Such genes were selected based on their 
Bonferroni-adjusted P-value <0.05 and fold difference higher than 2. Hierarchical clustering 
using Euclidean distance with all genes with Bonferroni P-value<0.05 was performed with 
Partek® Genomics Suite™. Gene Ontology (GO), used to further interpret the differentially 
expressed gene data set and to identify over-represented functional groups of genes, and Gene 
Set Enrichment Analysis (GSEA), used to highlight pathways over- or under-represented as a 
set, were also performed in Partek. Molecular networks related to differentially expressed 
genes were built via the Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, 
www.ingenuity.com) application using the “Core Analysis” function. Briefly, a data set 
  
containing differentially expressed genes and respective fold differences were first uploaded 
into the application. The genes were then correlated based on previous association between 
genes or proteins and known functional roles of genes. The biological relationship between 
two genes, represented as nodes, is shown as a line. Nodes with different shapes indicate 
different functional class. 
Isolation of cardiomyocytes and other cells  
Cardiomyocytes were isolated from whole NHR and HHR hearts as we previously described 
2. After 10 min incubation, cardiomyocytes were deposited in the bottom of tubes. The 
supernatant was considered to contain other cells than cardiomyocytes. Cardiomyocytes or 
other cells were pelleted by centrifugation at 4,000 RCF for 5 min in a refrigerated bench top 
centrifuge. Total RNA was extracted from both cardiomyocytes and other cells for each 
sample using the miRNeasy kit (Qiagen) as described above. cDNA and qPCR were 
performed as described above.  
Real-time Quantitative PCR (qPCR)  
First-strand complementary synthesis reaction was performed using the High Capacity cDNA 
Reverse Transcription Kit (Life Technologies). Primers were designed to flank an exon-exon 
junction using Primer3 5 and NCBI tool Primer Blast. Primers and conditions used for all 
qPCR are shown in Online Table 1. Amplification reactions used the SensiFastTM SYBR 
Low-ROX Kit qPCR reagent system (Bioline) in a Viia7 qPCR instrument (Life 
Technologies). Samples were run in duplicates. The specificity of the qPCR was ensured by 
melting curve analysis and electrophoresis in agarose gels (data not shown). The 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as reference transcript. 
Significance was assessed by 2-ΔΔCT method 6.   
Plasma measurement of LCN2  
In animal samples, after euthanasia, blood was immediately collected in EDTA tubes and 
centrifuged. Plasma was stored separately. Lcn2 plasma and left ventricle levels were 
measured by enzyme-linked immunosorbent assay (ELISA) in duplicates in neonatal and 
adult HHR and NHR using the Lipocalin-2 Rat ELISA Kit (Abcam) according to the 
supplier. Human plasma collected in heparin tubes was used to measure LCN2 levels using 
the Quantikine ELISA Human Lipocalin-2 Immunoassay (R&D Systems) according to the 
supplier. Inter- and intra-assay coefficients of variability were calculated and only less than 
15% variability was accepted (hence 7 human samples were excluded from further analyses). 
The overall intra-assay coefficient was 4.3% and the inter-coefficient was 4.5%.  
Immunohistochemistry 
Immunohistochemistry was performed using an anti-LCN2 Rabbit Polyclonal 
antibody (1:200 dilution, OriGene Technologies, TA322583), followed by the 
EnVision+System-HRP (Dako). In immunohistochemistry images, the positive staining 
(Lcn2) was the standard brown while the counterstain was haematoxylin (stains blue). Images 
were obtained in an EVOS® XL Cell Imaging System (Life Technologies) microscope using 
a 400x magnification. 
Protein measurement of Lcn2 by Western Blots 
Protein was extracted from left ventricle of 13 week old HHR and NHR by the use of RIPA 
buffer (Sigma-Aldrich) and 1% Halt Protease & Phosphatase Inhibitor Cocktail (Thermo 
Scientific). Fifty micrograms of extracted rat proteins were resolved by 4–15% Mini-
PROTEAN® TGX™ Precast Gel (BioRad). Proteins were electroblotted on to a 
Nitrocellulose Membrane (Thermo Scientific). Membranes were blocked for two hours in 5% 
  
skim milk, then incubated overnight at 4oC with Anti-LCN2 Rabbit Polyclonal 
antibody (1:2500 dilution, OriGene Technologies, TA322583) or β-actin (1:5000 dilution, 
Cell Signalling, 3700) in blocking solution, followed by several washing steps in PBS-Tween 
20, 1 h at RT with secondary antibody (Lcn2: Anti-rabbit HRP-linked Antibody, 1:5000 
dilution, Cell Signalling, 7074S; and  β-actin: Anti-mouse HRP-linked Antibody, 1:5000 
dilution, Cell Signalling, 7076S) in blocking solution, and several washing steps in PBS-
Tween 20, before detection by enhanced chemiluminescence SuperSignal West Pico 
Substrate (Thermo Scientific) according to the manufacturer’s instructions. Images were 
captured with a UVITEC Alliance digital imaging system (Thermo Scientific). Bands were 
quantified using Image J software, and Lcn2 protein levels were calculated as a ratio relative 
to β-actin. Both 25 kDa monomer Lcn2 and Lcn2 complexed with matrix metallopeptidase 9 
(Mmp9) were measured.  
DNA sequencing 
Sanger sequencing was used to sequence 10,000 base pairs (bp) before and 2,000 bp after the 
Lcn2 gene (primers and conditions in Online Table 1). Briefly we extracted DNA using 
PureLink® Genomic Extraction kit (Life Technologies), and then amplified it with 
IMMOLASE DNA Polymerase (Bioline) in a themocycler (BioRad). PCR fragments were 
purified using the Wizard® SV Gel and PCR Clean-Up System (Promega) and send out for 
sequencing at AGRF. We sequenced the DNA of both HHR and NHR and align them to the 
sequence of both SHR and Fisher 344 (the two strains which originated the HHR and NHR), 
and the reference genome from the Rat Genome Database (version 5). 
Lcn2-knockout 
Whole body and heart size of adult (12-13 week-old) whole-body Lcn2 knockout (Lcn2-KO, 
n=6) and age-matched wild-type mice C57BL/6 (n=4) were measured upon death, and CWI 
was calculated as described above. Both Lcn2-KO and wild-type mice were sourced from 
Prof Alan Aderem (University of Washington) 7. 
Vector containing Lcn2 
The pExpress vector containing the cDNA for the rat Lcn2 (Thermo Scientific, catalogue 
number ID MRN1768-98079404) was transformed into JM109 competent cells (Promega). 
Constructs were cultivated in plates of Luria-Bertani (LB) medium containing agar and 
ampicillin (50 μg/ml). Individual colonies were selected and the presence of the vector was 
confirmed by restriction enzyme and Sanger sequencing. The colonies containing the vector 
were cultured in LB medium overnight, and plasmids were extracted using a PureLink™ 
HiPure Plasmid Filter Kit (Life Technologies). To create an empty pExpress vector to be 
used as a control, Lcn2 sequence was cut out of the plasmid using the restriction enzymes 
Not1 and SmaI (Promega). DNA Polymerase I Large (Klenow) Fragment (Promega) was 
used to generate blunted ends. The product was run in a 1% agarose gel, and the band of the 
correct size was purified from the gel using the Wizard SV Gel and PCR Clean-Up system 
(Promega). 163 ng of this purification was ligated using T4 DNA Ligase (Life Technologies), 
and this was transformed into competent cells as described above. The sequence of both 
plasmids has been confirmed by Sanger DNA sequencing using T7 and sp6 universal primers 
as a service at the Australian Genome Research Facility (AGRF) as a service.  
H9c2 Cell Transfections 
The rat embryonic ventricular myocardial cells (H9c2: ATCC® CRL1446™) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), containing 10% fetal bovine serum (FBS) 
(all from Life Technologies) at 37oC with 5% CO2. Cell culture medium was replaced every 
48–72 hours. This cell line was specifically chosen because it has similar hypertrophic 
  
properties as rat primary neonatal cardiomyocytes.8 The cells were purchased from ATCC, 
and short tandem repeats (STR) profiling was not available for this rat cell line. Moreover, 
cells were regularly tested for mycoplasma contamination using Hoechst staining (Life 
Technologies) and a Nikon C2 confocal microscope, with negative results during 
experiments. H9c2 cells were cultured in 6- to 24-well plates and transfected with 2ng/ml of 
Lcn2 or empty (pExpress only) plasmid using Lipofectamine 2000TM (Life Technologies) in 
cells at 50% confluence. Untransfected and mock controls were also included. Preliminary 
experiments were used to determine the best concentration of cells, reagents and vector to 
have similar levels of Lcn2 as in HHR, so copying physiological levels (Fig. S6). The 
minimum concentration of vector and transfection reagents, according to the manufacturer’s 
recommendations, were used. All in vitro experiments were independently repeated 3 times, 
each time in triplicates (i.e., total of 9 biological replicates). Experiments always included 
Lcn2 vector, empty plasmid, untransfected cells and a positive control.  
RNA-sequencing and molecular pathways 
Total RNA was extracted from whole snap-frozen hearts of Lcn2-KO mice and cells 
transfected with Lcn2 plasmid for 48h (and respective controls) using the miRNeasy Mini kit 
(Qiagen). The RNA from 3 samples of each group was sent to RNA-sequencing at AGRF 
according to the manufacturer’s instructions using the Illumina HiSeq platform (v3 chemistry 
100bp paired-end sequencing). Each sample was considered an individual sample and no 
pooling was performed. 
Read quality was assessed using the FastQC software version 0.10.1 
(www.bioinformatics.babraham.ac.uk/projects/fastqc/), revealing high quality sequence and 
base scores (mean PHRED scores: overall=35.8, 1bp start=32.4, 100bp end=31.5), and thus 
read trimming was not applied. Analysis of differential expression was performed in the R 
statistical programming environment (version 3.1.0) using Rsubread (version 1.14.2) and 
edgeR (version 3.6.8) Bioconductor packages 9. Paired-end 100bp Illumina reads were 
aligned to mouse (UCSC mm10 assembly) and rat genomes (UCSC rn5 assembly) at the 
gene-level using Rsubread aligner with 82.4% and 92.1% of reads successfully mapped 
overall for mouse and rat samples, respectively. For individual sample and alignment 
characteristics (i.e. number of paired reads, % mapped, indels, etc) see Online Table 2. 
Differential expression (DE) of genes was assessed with edgeR. Genes with 1-count-
per-million mapped reads or less in at least one of the samples were filtered out due to 
unreliable data in any sample. Count data was then normalized by finding a set of scaling 
factors for the library sizes that adjust for compositional differences between samples and 
also help account for any biases due to changes in highly expressed genes 10. Scaling factors 
were calculated using the trimmed mean of M values (TMM) method 9, 11. Biological 
coefficient of variation (BCV) was estimated using the common dispersion method (negative 
binomial dispersion by conditional maximum likelihood) for both mouse (BCV=0.250) and 
rat (BCV=0.023) samples. Both values were above the threshold (BCV=0.01) suggested for 
technical replicates in the edgeR User’s Guide indicating sufficient biological variability for 
analysis. BCV is derived from total CV, which is the sum of estimated true biological (BCV) 
and technical variation (i.e. measurement error) across libraries. Gene-specific dispersions 
were then estimated using the empirical Bayes method (tagwise negative binomial) where 
expression differences that are consistent between replicates are more highly weighted than 
those that are not, which is necessary so that DE is not driven by outliers. DE was calculated 
by computing genewise exact tests for differences in the means between both groups (wild-
type and knockout in mouse, control and transfected in rat) of negative-binomially distributed 
counts in edgeR. P-values were adjusted for multiple testing using the Benjamini-Hochberg 
  
correction 12 with a FDR<0.05. 
To check experimental data quality with sample clustering and heatmaps, variance 
stabilized expression values (i.e. normalized for variation library size/sequencing depth) were 
generated using the R package DESeq (version 1.16.0) 13. This data was entered for the top 
100 (ranked by unadjusted P-value, all P<0.01) differentially expressed genes into principal 
component analysis (PCA), hierarchical cluster analysis (HCA), gene-gene heatmap and 
gene-sample heatmap analysis in R. PCA and HCA confirmed control and experimental 
group differences (data not shown) and also provided further insight into genes that are 
associated with the main experimental manipulations in both the rat and mouse studies. 
GO enrichment analysis was performed on filtered lists (all genes with unadjusted 
edgeR P-value<0.05, including 529 and 721 rat and mouse genes, respectively) of 
differentially expressed genes using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) 14, 15 to ask which Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways were enriched in genes differentially expressed in both mouse 
and rat samples. Circular plots were produced with the R package Rcircos (version 1.1.2) 16 
and show the top 100 differentially expressed genes ranked by edgeR P-value and enriched 
pathways identified in KEGG. 
Number of cells and cell size 
We counted the number of cells after 48 hours of transfection by haemocytometry with the 
use of a Countess® Automated Cell Counter (Life Technologies). Wheat germ agglutinin 
(WGA) and Hoechst staining were performed as previously described to measure cell size 17. 
Cell size was measured in 10 different fields per slide obtained in a Nikon C2 confocal 
microscope using a 400x magnification. 823 cells in average were measured for each 
condition. Angiotensin II (Sigma-Aldrich) added to the cells for 48h at final concentration of 
0.1 µM was used as a positive control. 
Cell cycle arrest 
To estimate cell proliferation, we counted phospho-histone H3 (pH3) stained cells after 
transfection with Lcn2 vector as described above. 500 nM of colcemid (Merck Biosciences), 
added 2 hours before fixing cells, was used as positive control. Briefly, cells on 12mm poly-
D-lysine/laminin coated coverslips were stained with pH3 and DAPI for fluorescence 
imaging as described somewhere else 18. We used the primary pH3 anti-rabbit antibody 
(Millipore, Cat# 06-570, 1:100 dilution) and secondary goat anti-rabbit AlexaFluor-488 
antibody (Invitrogen, 1:500 dilution). Ten images per slide were obtained in a Nikon C2 
confocal microscope using a 200x magnification (Fig. S7).  
Apoptosis 
Cell death and apoptosis were measured by flow cytometry using an Annexin-V: FITC 
Apoptosis Detection Kit I (BD Pharmingen, Cat No. 556547).  Cells were detached from 
plate by mild trypsinization (Life Technologies) and were washed twice with cold phosphate 
buffer saline (PBS). Cells were then resuspended in binding buffer and stained with annexin-
V-FITC and propidium iodide as per manufacturer’s protocol. The stained cells were 
analysed using FACS Aria II (BD Biosciences). The data analysis was performed using FCS 
express (version 4) research edition analytical software. 100 nM staurosporine was used as a 
positive control. 
Human Samples 
Two independent cohorts were used (Online Tables 3 and 4). One hundred and twenty one 
subjects were selected from a prospective cohort of type-2 diabetes (Online Table 3) 19. Left 
  
ventricle (LV) structure and function was studied using transthoracic echocardiography – 
Acuson Sequoia 512 (Acuson, Mountain View, CA, USA) with 3.5 MHz scanning frequency 
phased-array transducer. From the ultrasound images, LV structure, systolic and diastolic 
function were measured following the guidelines of American Society of Echocardiography, 
as previously described 20, 21. Cardiac hypertrophy was defined as LV mass indexed to the 
body surface of > 95 g/m2 in women and > 115 g/m2 in men 19. E/E'- ratio was calculated 
using the average values of lateral and septal e' velocity 21. Other phenotypes, including blood 
pressure, were also available. Subjects with chronic kidney disease were excluded due to 
previous association with LCN2 in the literature 22. Plasma samples were collected in heparin 
tubes, and stored at –80 ºC. All subjects gave informed consent and the study was approved 
by human ethics committee at the Austin Hospital, and ratified at Federation University 
Australia. 
The Cardiovascular Risk in Young Finns Study (YFS) is an ongoing population-based 
prospective study started in 1980 to study the emergence and progression of cardiovascular 
disease risk factors from childhood 23. 4,320 individuals from six age groups (3, 6, 9, 12, 15, 
and 18 years of age) were randomly recruited from the five major population centres of 
Finland (Helsinki, Kuopio, Turku, Oulu, and Tampere). A total of 3,596 individuals 
participated in the original study and 2,064 individuals responded to the 2011 follow-up 
study. Transcriptome-wide microarray profiling, genome-wide genotyping, GlycA, and 
echocardiography measurements were available for subsets of these 2,064 individuals 24-27. 
Baseline cohort characteristics are provided in Online Table 3. Ethics were approved by the 
Joint Commission on Ethics of the Turku University and the Turku University Central 
Hospital. 
Venous blood samples were collected after an overnight fast and serum samples were 
aliquoted and stored at –70ºC. Samples were collected after an overnight fast for the YFS 
cohort 23.  
GlycA measurement 
A proton nuclear magnetic resonance platform (Bruker AVANCE III, 500 MHz 
spectrometer) was used to quantify the concentrations of 106 circulating lipids, proteins, and 
metabolites from serum (including GlycA and total triglycerides) in the YFS cohort. Detailed 
experimental protocols are described in 28.  
CRP measurement 
High-sensitivity C-reactive protein (CRP) was quantified from YFS serum samples using an 
automated analyser with a latex turbidimetric immunoassay kit.  
Coexpression networks and quantitative trait locus 
Transcriptome wide microarray profiling was performed on whole blood for 1,650 
individuals in the YFS as previously described 24. Briefly, stabilised total RNA was obtained 
from whole blood for individuals in the YFS using the PAXgene Blood RNA System. An 
Eppendorf BioPhotometer was used to evaluate RNA concentrations and purity and the 
isolation process validated using an Agilent RNA 6000 Nano Chip Kit. RNA was hybridized 
to Illumina HT-12 (version 4) BeadChip arrays and raw probe data was exported with the 
Illumina BeadStudio software. Negative control probes were used to background correct the 
microarrays. Both positive and negative control probes were used to quantile normalised 
using the limma R package 29. Probe intensities were reported on a log2 scale. 
Coexpression was calculated for genes composing the previously described neutrophil 
module 30 as the Spearman correlation coefficient between the gene expression microarray 
  
data. The average probe intensity across samples was taken for genes with multiple probes 
(DEFA1B, OLFM4, COL17A1). Edges in the interaction network were defined as the 
absolute value of the coexpression exponentiated to the power 4 as in 30. The connectivity of 
each gene was calculated as the sum of edge weights to all other genes in the module then 
scaled by the connectivity of DEFA1B; the most connected gene. The scaled connectivity is a 
measure of biological importance to the network 31. A summary profile of module expression 
was calculated as the first eigenvector of a principal components analysis of the module’s 
gene expression data 32. The summary expression profile explained 57% of the variance the 
module’s gene expression matrix. 
Genome-wide genotyping was carried out on whole blood samples for 2,442 
individuals participating in the 2001 follow-up study of the YFS as previously described 25. 
Sample and genotype quality control was performed for these 2,442 individuals. Briefly, 
DNA was extracted and genotyped on a custom 670K Illumina BeadChip array sharing 
562,643 SNPs with the Illumina 610 BeadChip array. The custom array removed poorly 
performing SNPs from the 610 array and improved copy number variation coverage 25. 
Genotypes were called using the Illuminus genotype calling algorithm 33. 2 individuals were 
removed after initial clustering (call rate < 90%) and 54 samples were subsequently removed 
following Sanger genotyping pipeline quality control (low call rate: < 90%, failing 
heterozygosity tests, duplicate samples: >98% concordance on pairwise comparison, 
previously unknown relationship: >70% concordance on pairwise comparison, or failing 
Sequenom genotype fingerprinting: < 90% concordance for > 10 genotypes). 546,770 SNPs 
passed quality control. 3 individuals were removed due to low genotyping success (< 95%) 
and 1 individual was removed for failing sex checks. 51 individuals were excluded due to 
previous unknown close relation to another sample (pairwise identity by descent pi-hat > 0.2) 
and 2 individuals were removed due to cryptic relatedness. Missing genotypes and un-typed 
SNPs were imputed using the 1000 Genomes Phase 1 (v3) reference panel. Imputed and 
genotyped SNPs were subsequently excluded where the genotype calling probability for any 
allele < 90%, information score < 0.4, minor allele frequency < 1% or Hardy Weinberg 
equilibrium P-value < 5 x 10-6. A combined total of 6,721,082 directly genotyped and 
imputed SNPs passed quality control. 
Module quantitative trait loci (QTLs) were identified for 1,386 individuals with 
matched genotype and gene expression data in the YFS through a genome-wide scan for 
SNPs associated with the summary expression profile using the 1.90 beta (version 3.32) 
software. Individual associations were tested using a linear model of minor allele dosage on 
neutrophil module summary expression. A SNP was considered a module QTL where P < 5 
x 10-8 (genome-wide significance). Models were adjusted for age, sex, and the first two 
principal components of the genotype data. The module QTL rs13297295 on chromosome 9 
was further tested for an association with expression levels LCN2 using the same model. 
Rs13297295 was also tested for association with GlycA and CRP in the 1,712 individuals 
with matched genotype and GlycA or CRP levels. 
LCN2 mRNA levels in human heart  
We used data in the repository GEO series GSE1145 to investigate the levels of LCN2 in 
human idiopathic dilated hearts (n=11 control hearts and n=15 idiopathic dilated hearts). We 
performed a whole-genome analysis using the GEO tools, including false discovery rate 
(FDR) adjustment for multiple comparisons, to determine whether LCN2 was over-expressed 
in human idiopathic dilated hearts.  
  
Table S1. Primers and conditions used to validate microarray gene expression results. 
Official gene 
symbol 
GenBank 
Accession # 
Primer Sequence (5’  3’) Concentration Product 
length  
Annealing 
temperature 
Rat Gapdh NM_017008.3  F: GGGGCTCTCTGCTCCTCCCTG 200 nM 108 bp 58ºC 
  R: ACGGCCAAATCCGTTCACACCG    
Rat Lcn2 NM_130741.1  F: GGGCTGTCCGATGAACTGAA 200 nM 98 bp 58ºC 
  R: CATTGGTCGGTGGGAACAGA    
Human ACTB NM_001101 F: CGCGAGAAGATGACCCAGAT 
R: GAGTCCATCACGATGCCAGT 
200 nM 119 bp 66 ºC 
Human LCN2 NM_005564.3 
 
F: CTACGGGAGAACCAAGGAGC 
R: CACTGGTCGATTGGGACAGG 
200 nM 114 bp 66ºC 
Sequencing primers 
 
Fragment 1 NM_130741.1  F: GGGAGTTTGAGGCTACCTGG 
R: ATATTGTGCTTCCCTCCCCG 
500 nM 1144 bp 55ºC 
Fragment 2 NM_130741.1  F: AGGTCAGGAGCAGCAAACAG 
R: TACTAGGTCCGATGTGTGCC 
500 nM 1339 bp 55ºC 
Fragment 3 NM_130741.1  F: TCAACAGGATGTGCTGGCAA 
R: CAGGGTTTCACCTGACGAGG 
200 nM 984 bp 58ºC 
Fragment 4 NM_130741.1  F: TGCGGTCCAGAAAGAAAGACA 
R: GACACCCTTCTCCCAGCAAC 
200 nM 909 bp 58ºC 
Fragment 5 NM_130741.1  F: AATGGACAGGACTCGGGGAA 
R: TCGCTCCTTCAGTTCATCGG 
200 nM 976 bp 58ºC 
Fragment 6  NM_130741.1  F: ACTTATGGAGTGTCCTGCGG 
R: AACACAGGTGGATGGGGAGA 
200 nM 950 bp 58ºC 
Fragment 7 NM_130741.1  F: CAAGTCTGAGGGTTCGTTTGT 
R: ACACAGGTGGATGGGGAGA 
200 nM 982 bp 58ºC 
Fragment 8  NM_130741.1  F: TGTCTGCCGCTCCATCTTTC 
R: ACCTTCCTGGCCCTAGACAT 
200 nM 987 bp 58ºC 
*F: forward primer, R: reverse primer, bp: base pairs. 
  
Table S2. RNA-sequencing alignment characteristics of individual sample. 
Sample 
Name 
Species Treatment Paired 
Reads 
Data Yield (bp) # Mapped % Mapped Correctly 
paired 
# Indels 
LCN2_KO_1 mouse Lcn2 knockout 14,884,071 2.98 Gb 11,954,145 80.3 9,773,674 46,999 
LCN2_KO_2 mouse Lcn2 knockout 18,268,306 3.65 Gb 15,479,156 84.7 12,730,249 61,344 
LCN2_KO_4 mouse Lcn2 knockout 18,081,296 3.62 Gb 15,286,738 84.5 12,666,558 60,985 
WT_7 mouse Wild-type 18,478,701 3.70 Gb 14,802,202 80.1 12,280,683 62,887 
WT_8 mouse Wild-type 20,477,226 4.10 Gb 17,082,133 83.4 13,926,290 65,430 
WT_9 mouse Wild-type 19,197,759 3.84 Gb 15,633,393 81.4 12,863,795 59,517 
P_1 rat Empty plasmid 18,079,037 3.62 Gb 16,643,663 92.1 13,676,516 120,877 
P_2 rat Empty plasmid 18,570,379 3.71 Gb 17,095,842 92.1 13,966,919 127,350 
P_3 rat Empty plasmid 16,296,670 3.26 Gb 14,986,199 92.0 12,217,148 110,047 
L_1 rat Lcn2 plasmid 17,256,951 3.45 Gb 15,898,212 92.1 13,017,963 117,624 
L_2 rat Lcn2 plasmid 16,652,741 3.33 Gb 15,343,993 92.1 12,576,273 113,638 
L_3 rat Lcn2 plasmid 17,646,480 3.53 Gb 16,252,059 92.1 13,287,420 117,522 
Total 
  
213,889,617 42.79 Gb 
    
  
Table S3. Characteristics of the participants in the type 2 diabetes cohort. 
Characteristic  Subjects without LVH 
(n=84) 
Subjects with LVH 
(n=30) 
P-value 
Age (years) 61.2 ± 9.6 65.6 ± 10.5 0.039 
Male sex, n (%) 56 (67%) 14 (47%) 0.08 
BMI (kg/m2) 31.5 ± 6.6 31.9 ± 4.9 0.77 
eGFR (ml/min/1.73cm2) 86.4 ± 19.4 90.9 ± 25.5 0.32 
Lcn2 (ng/ml)* 38.7 [35.2-41.7] 36.0 [28.6, 45.2] 44.0 [29.8, 61.4] 
 
49.1 [ 9.8-5 .5] 36.0 [28.6, 45.2] 44.0 [29.8, 61.4] 
 
0.017 
Systolic BP (mmHg) 141 ± 19 146 ± 18 0.22 
Hypertension, n (%) 71 (85%) 27 (90%) 0.56 
Structure    
Interventricular septum thickness (cm) 0.98 ± 0.16 1.20 ± 0.18 <0.0001 
Posterior wall thickness (cm) 0.96 ± 0.16 1.15 ± 0.12 <0.0001 
LV end diastolic dimension (cm) 4.8 ± 0.5 5.3 ± 0.6 <0.0001 
LV end systolic dimension (cm) 2.8 ± 0.5 3.2 ± 0.6 0.001 
Function    
LV ejection fraction (%) 64 ± 9 63 ± 9 0.73 
s´ medial (cm/s) 6.9 ± 1.4 6.6 ± 0.5 0.28 
E (m/s) 0.75 ± 0.20 0.80 ± 0.19 0.16 
A (m/s) 0.81 ± 0.17 0.89 ± 0.18 0.040 
E/A ratio 0.93 ± 0.26 0.94 ± 0.31 0.97 
E' (cm/s) 6.8 ± 1.9 5.8 ± 1.7 0.016 
E/E' ratio 11.4 ± 3.5 15.2 ± 4.5 <0.0001 
DT (ms) 215 ± 52 228 ± 59 0.26 
IVRT (ms) 92 ± 18 92 ± 30 0.97 
Legend: Data presented as mean ± standard deviation and proportions n. *Lcn2 levels shown as the mean [95% CI]. The P-values represent the 
differences in parameters in those without LVH and with LVH. Legend: LVH, left ventricle hypertrophy; BMI, body mass index, eGFR, estimated 
glomerular filtration rate; Lcn2, lipocalin-2; BP, blood pressure; CI: confidence intervals.  
  
Table S4. Characteristics of individuals from the YFS cohort. 
Characteristic  Prevalence in YFS 
Mean age (and range) in years 41.8 (34–49) 
Number of individuals 2,064 
Male sex, n (%) 936 (45%) 
BMI (kg/m2) 26.5 ± 5.1 
Body surface area (m2) 1.9 ± 0.2 
GlycA (mmol/L) 1.6 ± 0.2 
CRP (mg/L) 1.7 ± 3.2 
Triglycerides (mmol/L) 1.4 ± 0.8 
LCN2 microarray probe intensity 10.0 ± 0.96 
Systolic blood pressure (mmHg) 119 ± 14 
Use of antihypertensive therapy, n (%) 197 (10%) 
Use of lipid-lowering therapy 75 (4.0%) 
Disease events, n (%)  
Prevalent CVD 20 (0.7%) 
Prevalent diabetes 35 (1.3%) 
Prevalent cancer 40 (1.4%) 
Prevalent immunodeficiency 10 (0.4%) 
Recent febrile infection 93 (4.6%) 
Structure  
Interventricular septum thickness (cm) 0.73 ± 0.09 
LV mass (g/m2) 135 ± 35 
Relative wall thickness to LV diameter (%) 28.1 ± 3.8 
Function  
Heart rate during echo (beats per minute) 62 ± 10 
LV ejection fraction (%) 58.3 ± 3.6 
LV cardiac output (L/minute) 4.7 ± 1.3 
LV volume during diastole (mL) 131 ± 32 
Ratio of LV mass to end diastolic volume 1.04 ± 0.21 
E/A ratio (log-scale) 0.41 ± 0.24 
E/E' ratio (log-scale) 1.55 ± 0.21 
Systolic myocardial velocity (s’) (cm/s)  
measured from lateral wall 13.7 ± 3.3 
measured from medial wall 11.0 ± 1.9 
Isovolumic relaxation time (IVRT) (ms)  
measured from lateral wall 104 ± 22 
measured from medial wall 123 ± 25 
Mitral E-wave declaration time (DT) (ms) 217 ± 38 
Legend: Data presented as mean ± standard deviation and proportions n (%). LV: left 
ventricle; BMI: body mass index; CRP: C-reactive protein; CVD: cardiovascular disease. 
Prevalent disease indicates events occurring prior to sample collection while incident disease 
indicates events occurring after sample collection.  
 
  
Table S5. Linear regression of LV phenotypes on LCN2 expression in the YFS. Models were adjusted for age and sex. Effect size indicates 
standard deviation (SD) change in left ventricular (LV) phenotype per SD increase in LCN2 expression.  
LV Phenotype Effect size 95% confidence interval P–value 
LV cardiac output 0.11 [0.066, 0.16] 3 x 10-6 
Heart rate during echo 0.12 [0.068, 0.17] 6 x 10-6 
LV mass 0.084 [0.043, 0.12] 5 x 10-5 
E/A ratio –0.084 [0.043, 0.12] 5 x 10-4 
Thickness of interventricular septum 0.077 [0.032, 0.12] 8 x 10-4 
LV volume during diastole (end diastolic volume) 0.048 [0.0073, 0.089] 0.02 
LV isovolumic relaxation time measured from the lateral wall –0.057 [–0.11, –0.0074] 0.02 
Ejection fraction –0.043 [–0.093, 0.0077] 0.10 
E/E' ratio 0.034 [–0.016, 0.083] 0.18 
Ratio of LV mass to end diastolic volume 0.035 [–0.017, 0.087] 0.19 
LV isovolumic relaxation time measured from the medial wall –0.020 [–0.070, 0.030] 0.43 
Systolic myocardial velocity measured from the medial wall 0.020 [–0.030, 0.070] 0.43 
Relative LV wall thickness to diameter 0.018 [–0.032, 0.069] 0.47 
Systolic myocardial velocity measured from the lateral wall –0.014 [–0.064, 0.036] 0.59 
Mitral E-wave declaration time –0.00004 [–0.50, 0.050] 1.00 
  
 
 
  
  
Table S6. Correlation of plasma LCN2 with echocardiogram parameters in the type 2 diabetes 
cohort. 
Structure Correlation coefficient 
(Spearman Rho) 
P-value 
Interventricular septum thickness (cm) 0.077 0.418 
Posterior wall thickness (cm) 0.165 0.079 
LV end diastolic dimension (cm) 0.159 0.091 
LV end systolic dimension (cm) 0.146 0.126 
   
Function   
LV ejection fraction (%) -0.052 0.587 
S´ medial (cm/s) -0.169 0.095 
E (m/s) -0.258 0.006 
A (m/s) 0.081 0.399 
E/A ratio -0.185 0.051 
E´ (cm/s) -0.132 0.162 
E/E´ ratio 0.156 0.100 
DT (ms) 0.16 0.090 
IVRT (ms) 0.038 0.730 
  
Table S7. Transcriptome-wide gene expression array results showing genes differentially expressed in the heart of neonatal HHR (n=8) and 
NHR (n=8) (only showing genes with P-value adjusted by Bonferroni <0.05 and fold difference >2).  
Gene Symbol RefSeq Bonferroni (P-value) Fold Change QTL cardiac mass 
Akr1b10 NM_001013084 0.00003010000 2.81 
 
Bphl NM_001037206 0.00027292800 2.10 Cm34, Cm55 
Btnl2 ENSRNOT00000060366 0.00041218200 2.40 
 
Car4 NM_019174 0.00629238000 –2.06 Cm73, Cm31, Cm78, Cm51, Cm33, Cm44, Cm75 
Endog NM_001034938 0.00000677000 –2.33 Cm43, Cm46, Cm48 
Hebp2 NM_001107515 0.00069056300 2.01 
 
Htr2a ENSRNOT00000013408 0.00001750000 3.18 
 
Itgbl1 NM_001017505 0.00005030000 2.58 
 
Lcn2 ENSRNOT00000018776 0.00000000007 5.02 Cm10, Cm43, Cm46, Cm48 
LOC100270669 NM_001144957 0.00348216000 –2.08 Cm29, Cm49 
Med22 NM_001077679 0.00000000009 3.07 
 
Nt5c3a ENSRNOT00000058703 0.00020376200 2.59 
 
Pex3 ENSRNOT00000021524 0.00005840000 2.36 
 
Pop5 NM_001105752 0.01728910000 –2.41 Cm5, Cm72, Cm45, Cm76 
RGD1309362 BC098065 0.00349021000 2.29 
 
RGD1561200 BC160898 0.00000009720 4.47 
 
Serhl2 NM_001130579 0.00000092500 2.28 Cm27 
Trpm8 NM_134371 0.00004230000 –2.79 Cm21, Cm53 
Vnn1 NM_001025623 0.00002730000 2.03 
 
Wdr46 NM_212491 0.00000164000 2.54 
 
Zfp347 NM_133390 0.00934935000 2.43 
 
Positive values indicate higher expression in the HHR, and negative values indicate higher expression in the NHR.  
Legend: QTL, quantitative trait locus.
  
Table S8. Gene ontology analysis with all genes differentially expressed with Bonferroni-adjusted P-value <0.05. 
Function Type Enrichment 
Score 
Enrichment P-
value 
cell-cell adhesion biological process 10.51 0.00003 
antigen processing and presentation biological process 9.36 0.00009 
antigen processing and presentation of exogenous 
peptide antigen via MHC class II 
biological process 8.09 0.00031 
cell surface cellular component 7.73 0.00044 
mitochondrion cellular component 7.58 0.00051 
intracellular membrane-bounded organelle cellular component 7.44 0.00059 
myosin heavy chain binding molecular function 7.33 0.00066 
response to interferon-alpha biological process 6.83 0.00109 
membrane cellular component 6.70 0.00123 
neuromuscular process biological process 6.62 0.00134 
retinol metabolic process biological process 6.62 0.00134 
retinal dehydrogenase activity molecular function 6.10 0.00225 
LRR domain binding molecular function 6.10 0.00225 
synaptic transmission, glutamatergic biological process 5.87 0.00281 
homotypic cell-cell adhesion biological process 5.82 0.00298 
secretion by cell biological process 5.82 0.00298 
cardiac right ventricle morphogenesis biological process 5.57 0.00380 
heterotrimeric G-protein complex cellular component 5.38 0.00459 
adherens junction cellular component 5.38 0.00459 
NADPH binding molecular function 5.36 0.00472 
spectrin binding molecular function 5.36 0.00472 
water channel activity molecular function 5.36 0.00472 
plasma membrane cellular component 5.33 0.00484 
heparin binding molecular function 5.32 0.00492 
positive regulation of cell death biological process 5.21 0.00545 
  
positive thymic T cell selection biological process 5.16 0.00573 
generation of precursor metabolites and energy biological process 5.16 0.00573 
multicellular organismal response to stress biological process 5.16 0.00573 
response to cold biological process 5.05 0.00640 
MHC class II protein complex cellular component 4.99 0.00683 
lysosome cellular component 4.86 0.00773 
cell adhesion molecule binding molecular function 4.83 0.00801 
chaperone mediated protein folding requiring 
cofactor 
biological process 4.83 0.00801 
fascia adherens cellular component 4.83 0.00801 
dorsal/ventral neural tube patterning biological process 4.54 0.01064 
myoblast differentiation biological process 4.54 0.01064 
water transport biological process 4.54 0.01064 
laminin binding molecular function 4.42 0.01208 
anterior/posterior axis specification biological process 4.42 0.01208 
positive regulation of apoptotic process biological process 4.38 0.01251 
apoptotic process biological process 4.36 0.01281 
olfactory bulb development biological process 4.30 0.01359 
fibroblast growth factor receptor binding molecular function 4.30 0.01359 
SNAP receptor activity molecular function 4.30 0.01359 
immune response biological process 4.28 0.01385 
cytoplasmic membrane-bounded vesicle cellular component 4.26 0.01410 
innate immune response biological process 4.19 0.01520 
structural constituent of muscle molecular function 4.08 0.01686 
response to drug biological process 4.03 0.01782 
protein homotetramerization biological process 3.99 0.01844 
protein homotrimerization biological process 3.98 0.01860 
positive regulation of calcium-mediated signalling biological process 3.98 0.01860 
positive regulation of cardiac muscle cell 
proliferation 
biological process 3.98 0.01860 
  
amino acid transmembrane transporter activity molecular function 3.98 0.01860 
protein sumoylation biological process 3.98 0.01860 
trans-Golgi network cellular component 3.97 0.01883 
blood vessel development biological process 3.94 0.01937 
oxidation-reduction process biological process 3.91 0.02001 
cell-cell junction cellular component 3.87 0.02083 
basolateral plasma membrane cellular component 3.86 0.02100 
cytoplasm cellular component 3.83 0.02170 
positive regulation of smooth muscle cell 
proliferation 
biological process 3.76 0.02338 
integrin complex cellular component 3.72 0.02426 
negative regulation of fibroblast proliferation biological process 3.72 0.02426 
eukaryotic cell surface binding molecular function 3.56 0.02838 
tubulin binding molecular function 3.56 0.02838 
lysosome organization biological process 3.56 0.02838 
RNA polymerase II transcription cofactor activity molecular function 3.49 0.03053 
ATPase activity, coupled to transmembrane 
movement of substances 
molecular function 3.49 0.03053 
positive regulation of BMP signalling pathway biological process 3.49 0.03053 
positive regulation of interleukin-4 biosynthetic 
process 
biological process 3.46 0.03136 
antigen processing and presentation, exogenous 
lipid antigen via MHC class Ib 
biological process 3.46 0.03136 
medium-chain fatty acid transport biological process 3.46 0.03136 
eye photoreceptor cell differentiation biological process 3.46 0.03136 
NADP-retinol dehydrogenase activity molecular function 3.46 0.03136 
thermoception biological process 3.46 0.03136 
5-phosphoribose 1-diphosphate biosynthetic 
process 
biological process 3.46 0.03136 
glycogen phosphorylase activity molecular function 3.46 0.03136 
  
mRNA cis splicing, via spliceosome biological process 3.46 0.03136 
platelet activating factor biosynthetic process biological process 3.46 0.03136 
myosin filament assembly biological process 3.46 0.03136 
ferroxidase activity molecular function 3.46 0.03136 
coated vesicle cellular component 3.46 0.03136 
chemical homeostasis biological process 3.46 0.03136 
protein localization to adherens junction biological process 3.46 0.03136 
photoreceptor cell outer segment organization biological process 3.46 0.03136 
death domain binding molecular function 3.46 0.03136 
thiol oxidase activity molecular function 3.46 0.03136 
cuticular plate cellular component 3.46 0.03136 
pulmonary myocardium development biological process 3.46 0.03136 
antigen processing and presentation of exogenous 
peptide antigen via MHC class I 
biological process 3.46 0.03136 
optic cup morphogenesis involved in camera-type 
eye development 
biological process 3.46 0.03136 
double-stranded RNA adenosine deaminase activity molecular function 3.46 0.03136 
supraspliceosomal complex cellular component 3.46 0.03136 
ubiquitin homeostasis biological process 3.46 0.03136 
tangential migration from the subventricular zone 
to the olfactory bulb 
biological process 3.46 0.03136 
positive regulation of dopamine receptor signalling 
pathway 
biological process 3.46 0.03136 
specification of organ position biological process 3.46 0.03136 
blood vessel endothelial cell proliferation involved 
in sprouting angiogenesis 
biological process 3.46 0.03136 
BMP signalling pathway involved in heart 
induction 
biological process 3.46 0.03136 
deltoid tuberosity development biological process 3.46 0.03136 
mesodermal cell differentiation biological process 3.46 0.03136 
  
cloacal septation biological process 3.46 0.03136 
regulation of pathway-restricted SMAD protein 
phosphorylation 
biological process 3.46 0.03136 
trachea formation biological process 3.46 0.03136 
bud elongation involved in lung branching biological process 3.46 0.03136 
regulation of cartilage development biological process 3.46 0.03136 
mesenchymal cell proliferation involved in ureteric 
bud development 
biological process 3.46 0.03136 
ureter smooth muscle cell differentiation biological process 3.46 0.03136 
plasma cell differentiation biological process 3.46 0.03136 
glycosphingolipid biosynthetic process biological process 3.46 0.03136 
connexin binding molecular function 3.46 0.03136 
nucleolar ribonuclease P complex cellular component 3.46 0.03136 
homocysteine S-methyltransferase activity molecular function 3.46 0.03136 
inorganic diphosphate transport biological process 3.46 0.03136 
sequestering of triglyceride biological process 3.46 0.03136 
NADH pyrophosphatase activity molecular function 3.46 0.03136 
response to iron(III) ion biological process 3.46 0.03136 
response to anoxia biological process 3.46 0.03136 
virus-infected cell apoptotic process biological process 3.46 0.03136 
folic acid transporter activity molecular function 3.46 0.03136 
creatine kinase activity molecular function 3.46 0.03136 
regulation of mast cell activation biological process 3.46 0.03136 
regulation of Fc receptor mediated stimulatory 
signalling pathway 
biological process 3.46 0.03136 
ganglioside catabolic process biological process 3.46 0.03136 
oligosaccharide catabolic process biological process 3.46 0.03136 
glycerol channel activity molecular function 3.46 0.03136 
forebrain cell migration biological process 3.46 0.03136 
negative regulation of lymphocyte activation biological process 3.46 0.03136 
  
axon midline choice point recognition biological process 3.46 0.03136 
olfactory bulb interneuron development biological process 3.46 0.03136 
Roundabout signalling pathway biological process 3.46 0.03136 
regulation of epidermal growth factor receptor 
signalling pathway 
biological process 3.46 0.03136 
localization within membrane biological process 3.46 0.03136 
low-density lipoprotein particle mediated signalling biological process 3.46 0.03136 
alanine-tRNA ligase activity molecular function 3.46 0.03136 
alanyl-tRNA aminoacylation biological process 3.46 0.03136 
transferrin transport biological process 3.46 0.03136 
endocardial cushion to mesenchymal transition 
involved in heart valve formation 
biological process 3.46 0.03136 
ascending aorta morphogenesis biological process 3.46 0.03136 
microsatellite binding molecular function 3.46 0.03136 
arterial endothelial cell differentiation biological process 3.46 0.03136 
cardiac vascular smooth muscle cell development biological process 3.46 0.03136 
protease binding molecular function 3.46 0.03138 
activation of MAPKK activity biological process 3.42 0.03275 
neuromuscular junction development biological process 3.35 0.03503 
response to retinoic acid biological process 3.35 0.03520 
regulation of cell shape biological process 3.24 0.03925 
cellular response to hydrogen peroxide biological process 3.22 0.03977 
protein kinase B signalling cascade biological process 3.22 0.03977 
cell adhesion biological process 3.20 0.04081 
positive regulation of cell projection organization biological process 3.18 0.04159 
T cell receptor binding molecular function 3.18 0.04159 
positive regulation of NK T cell activation biological process 3.18 0.04159 
neurotransmitter metabolic process biological process 3.18 0.04159 
smooth muscle cell migration biological process 3.18 0.04159 
positive regulation of ovulation biological process 3.18 0.04159 
  
peroxisome membrane biogenesis biological process 3.18 0.04159 
vitamin binding molecular function 3.18 0.04159 
biotin binding molecular function 3.18 0.04159 
rhythmic synaptic transmission biological process 3.18 0.04159 
sphingosine metabolic process biological process 3.18 0.04159 
regulation of striated muscle contraction biological process 3.18 0.04159 
glycosaminoglycan catabolic process biological process 3.18 0.04159 
morphogenesis of a polarized epithelium biological process 3.18 0.04159 
phospholipid dephosphorylation biological process 3.18 0.04159 
AP-1 adaptor complex cellular component 3.18 0.04159 
protein thiol-disulfide exchange biological process 3.18 0.04159 
dichotomous subdivision of terminal units involved 
in salivary gland branching 
biological process 3.18 0.04159 
epsilon DNA polymerase complex cellular component 3.18 0.04159 
phospholipid transporter activity molecular function 3.18 0.04159 
telomerase activity molecular function 3.18 0.04159 
telomere maintenance via recombination biological process 3.18 0.04159 
ferric-chelate reductase activity molecular function 3.18 0.04159 
fat pad development biological process 3.18 0.04159 
female meiosis I biological process 3.18 0.04159 
exploration behaviour biological process 3.18 0.04159 
intracellular distribution of mitochondria biological process 3.18 0.04159 
negative regulation of dendritic spine 
morphogenesis 
biological process 3.18 0.04159 
negative regulation of inclusion body assembly biological process 3.18 0.04159 
telencephalon regionalization biological process 3.18 0.04159 
negative regulation of T cell differentiation in 
thymus 
biological process 3.18 0.04159 
negative regulation of immature T cell proliferation 
in thymus 
biological process 3.18 0.04159 
  
tendon cell differentiation biological process 3.18 0.04159 
trachea development biological process 3.18 0.04159 
prostate gland morphogenesis biological process 3.18 0.04159 
negative regulation of prostatic bud formation biological process 3.18 0.04159 
regulation of morphogenesis of a branching 
structure 
biological process 3.18 0.04159 
negative regulation of thymocyte apoptotic process biological process 3.18 0.04159 
negative regulation of branching involved in 
ureteric bud morphogenesis 
biological process 3.18 0.04159 
epithelial structure maintenance biological process 3.18 0.04159 
cardiac muscle fibre development biological process 3.18 0.04159 
transepithelial transport biological process 3.18 0.04159 
nucleotide diphosphatase activity molecular function 3.18 0.04159 
nucleoside-triphosphate diphosphatase activity molecular function 3.18 0.04159 
nucleoside triphosphate catabolic process biological process 3.18 0.04159 
folic acid transport biological process 3.18 0.04159 
water transmembrane transporter activity molecular function 3.18 0.04159 
response to interferon-beta biological process 3.18 0.04159 
phosphatidylserine biosynthetic process biological process 3.18 0.04159 
beta-N-acetylhexosaminidase activity molecular function 3.18 0.04159 
selenocysteine incorporation biological process 3.18 0.04159 
negative regulation of chemokine-mediated 
signalling pathway 
biological process 3.18 0.04159 
regulation of translational fidelity biological process 3.18 0.04159 
negative regulation of vasodilation biological process 3.18 0.04159 
negative regulation of wound healing biological process 3.18 0.04159 
negative regulation of insulin secretion involved in 
cellular response to glucose stimulus 
biological process 3.18 0.04159 
muscular septum morphogenesis biological process 3.18 0.04159 
dorsal aorta morphogenesis biological process 3.18 0.04159 
  
pulmonary artery morphogenesis biological process 3.18 0.04159 
vascular smooth muscle cell development biological process 3.18 0.04159 
serine-type carboxypeptidase activity molecular function 3.18 0.04159 
centrosome cellular component 3.17 0.04214 
mediator complex cellular component 3.16 0.04222 
ATP hydrolysis coupled proton transport biological process 3.16 0.04222 
peptidyl-tyrosine dephosphorylation biological process 3.16 0.04222 
intercalated disc cellular component 3.16 0.04222 
embryonic hindlimb morphogenesis biological process 3.16 0.04222 
response to bacterium biological process 3.11 0.04473 
positive regulation of proteasomal ubiquitin-
dependent protein catabolic process 
biological process 3.11 0.04473 
odontogenesis biological process 3.11 0.04473 
negative regulation of MAP kinase activity biological process 3.11 0.04473 
adult walking behaviour biological process 3.05 0.04729 
actin cytoskeleton reorganization biological process 3.05 0.04729 
metal ion binding molecular function 3.04 0.04770 
receptor binding molecular function 3.03 0.04816 
sarcolemma cellular component 3.00 0.04956 
cation binding molecular function 3.00 0.04991 
blood vessel remodeling biological process 3.00 0.04991 
  
Table S9. Gene set enrichment analysis, based on gene ontology, of the gene list for differentially expressed genes between HHR and NHR (P<0.05). 
Gene Set Gene Set Description Number of 
Markers 
ES NES P-value HHR vs NHR 
60048 cardiac muscle contraction 30 –0.57 –1.99 <0.001 Down 
35335 peptidyl-tyrosine dephosphorylation 38 –0.56 –1.96 <0.001 Down 
97110 scaffold protein binding 25 –0.55 –1.93 <0.001 Down 
16459 myosin complex 42 –0.60 –1.90 <0.001 Down 
30017 sarcomere 26 –0.59 –1.99 <0.001 Down 
3774 motor activity 51 –0.53 –1.87 <0.001 Down 
55010 ventricular cardiac muscle tissue morphogenesis 26 –0.58 –1.87 <0.001 Down 
5089 Rho guanyl-nucleotide exchange factor activity 61 –0.53 –1.84 <0.001 Down 
45859 regulation of protein kinase activity 18 –0.67 –1.82 <0.001 Down 
35108 limb morphogenesis 24 –0.54 –1.78 <0.001 Down 
3777 microtubule motor activity 68 –0.48 –1.78 <0.001 Down 
45747 positive regulation of Notch signalling pathway 17 –0.66 –1.77 <0.001 Down 
32880 regulation of protein localization 40 0.49 1.81 <0.001 Up 
5216 ion channel activity 51 –0.51 –1.79 <0.001 Down 
45087 innate immune response 87 0.43 1.80 <0.001 Up 
9635 response to herbicide 17 0.59 1.82 <0.001 Up 
36094 small molecule binding 17 0.79 1.79 <0.001 Up 
42098 T cell proliferation 18 –0.66 –1.75 <0.001 Down 
16592 mediator complex 30 0.53 1.78 <0.001 Up 
30016 myofibril 46 –0.60 –1.79 <0.001 Down 
30506 ankyrin binding 21 –0.70 –1.75 <0.001 Down 
6730 one-carbon metabolic process 30 0.55 1.70 <0.001 Up 
17134 fibroblast growth factor binding 28 0.61 1.83 <0.001 Up 
8146 sulfotransferase activity 30 0.49 1.71 <0.001 Up 
10765 positive regulation of sodium ion transport 21 0.54 1.71 <0.001 Up 
45471 response to ethanol 139 0.43 1.71 <0.001 Up 
  
15171 amino acid transmembrane transporter activity 20 0.64 1.87 <0.001 Up 
5758 mitochondrial intermembrane space 43 0.56 1.72 <0.001 Up 
1965 G-protein alpha-subunit binding 22 0.54 1.67 <0.001 Up 
16925 protein sumoylation 23 0.52 1.65 <0.001 Up 
15807 L-amino acid transport 20 0.58 1.66 <0.001 Up 
9636 response to toxin 95 0.43 1.75 <0.001 Up 
19233 sensory perception of pain 68 0.42 1.66 <0.001 Up 
6164 purine nucleotide biosynthetic process 15 0.68 1.73 <0.001 Up 
10862 positive regulation of pathway-restricted SMAD 
protein phosphorylation 
23 0.71 1.73 <0.001 Up 
9615 response to virus 100 0.44 1.83 <0.001 Up 
6979 response to oxidative stress 126 0.39 1.62 <0.001 Up 
5771 multivesicular body 20 0.51 1.61 <0.001 Up 
71356 cellular response to tumor necrosis factor 42 0.46 1.61 <0.001 Up 
30838 positive regulation of actin filament 
polymerization 
32 0.45 1.57 <0.001 Up 
9725 response to hormone stimulus 100 0.38 1.54 <0.001 Up 
6103 2-oxoglutarate metabolic process 16 0.71 1.57 <0.001 Up 
34446 substrate adhesion-dependent cell spreading 23 0.54 1.63 <0.001 Up 
118 histone deacetylase complex 24 –0.47 –1.71 <0.001 Down 
70207 protein homotrimerization 21 0.48 1.55 <0.001 Up 
35265 organ growth 16 –0.56 –1.69 <0.001 Down 
10165 response to X-ray 20 0.49 1.55 <0.001 Up 
15908 fatty acid transport 18 0.56 1.57 <0.001 Up 
7031 peroxisome organization 21 0.57 1.59 <0.001 Up 
9966 regulation of signal transduction 26 –0.45 –1.68 <0.001 Down 
7266 Rho protein signal transduction 31 0.42 1.63 <0.001 Up 
5516 calmodulin binding 119 –0.39 –1.66 <0.001 Down 
1968 fibronectin binding 19 0.66 1.83 <0.001 Up 
30182 neuron differentiation 109 0.34 1.50 <0.001 Up 
  
16874 ligase activity 39 0.46 1.47 <0.001 Up 
1104 RNA polymerase II transcription cofactor activity 25 0.56 1.89 <0.001 Up 
187 activation of MAPK activity 64 –0.39 –1.63 <0.001 Down 
21549 cerebellum development 41 –0.41 –1.60 <0.001 Down 
43292 contractile fibre 17 –0.61 –1.63 <0.001 Down 
10524 positive regulation of calcium ion transport into 
cytosol 
15 –0.57 –1.62 <0.001 Down 
3333 amino acid transmembrane transport 34 0.65 1.93 <0.001 Up 
48513 organ development 16 –0.65 –1.62 <0.001 Down 
43274 phospholipase binding 16 –0.52 –1.55 <0.001 Down 
7050 cell cycle arrest 75 –0.40 –1.58 <0.001 Down 
10628 positive regulation of gene expression 163 0.33 1.39 <0.001 Up 
45597 positive regulation of cell differentiation 36 0.41 1.37 <0.001 Up 
5080 protein kinase C binding 42 –0.44 –1.56 <0.001 Down 
8289 lipid binding 94 0.33 1.38 <0.001 Up 
7528 neuromuscular junction development 28 –0.49 –1.53 <0.001 Down 
5604 basement membrane 77 –0.39 –1.50 <0.001 Down 
42391 regulation of membrane potential 60 –0.39 –1.51 <0.001 Down 
51091 positive regulation of sequence-specific DNA 
binding transcription factor activity 
75 –0.42 –1.49 <0.001 Down 
30667 secretory granule membrane 17 –0.50 –1.48 <0.001 Down 
50852 T cell receptor signalling pathway 32 –0.40 –1.46 <0.001 Down 
48485 sympathetic nervous system development 20 –0.51 –1.46 <0.001 Down 
8060 ARF GTPase activator activity 22 –0.50 –1.46 <0.001 Down 
51924 regulation of calcium ion transport 33 –0.40 –1.38 <0.001 Down 
10212 response to ionizing radiation 47 0.36 1.39 0.018 Up 
2020 protease binding 67 0.41 1.62 0.019 Up 
5215 transporter activity 133 0.36 1.51 0.019 Up 
43200 response to amino acid stimulus 47 0.47 1.59 0.019 Up 
45861 negative regulation of proteolysis 20 0.53 1.62 0.019 Up 
  
31667 response to nutrient levels 64 0.41 1.58 0.019 Up 
9617 response to bacterium 32 0.46 1.53 0.019 Up 
1937 negative regulation of endothelial cell 
proliferation 
25 –0.45 –1.55 0.019 Down 
7219 Notch signalling pathway 59 –0.34 –1.43 0.019 Down 
33077 T cell differentiation in thymus 31 0.49 1.45 0.020 Up 
70301 cellular response to hydrogen peroxide 30 0.50 1.70 0.020 Up 
42573 retinoic acid metabolic process 16 0.58 1.70 0.020 Up 
50776 regulation of immune response 20 0.47 1.55 0.020 Up 
15450 P-P-bond-hydrolysis-driven protein 
transmembrane transporter activity 
17 0.68 1.68 0.020 Up 
46686 response to cadmium ion 30 0.49 1.62 0.020 Up 
6829 zinc ion transport 18 0.63 1.58 0.020 Up 
5671 Ada2/Gcn5/Ada3 transcription activator complex 15 0.55 1.56 0.020 Up 
7610 behaviour 31 0.48 1.60 0.021 Up 
8301 DNA binding, bending 58 –0.56 –1.70 0.021 Down 
19003 GDP binding 33 0.67 1.58 0.021 Up 
86091 regulation of heart rate by cardiac conduction 16 –0.58 –1.66 0.021 Down 
7417 central nervous system development 71 0.34 1.36 0.021 Up 
16023 cytoplasmic membrane-bounded vesicle 89 –0.34 –1.43 0.021 Down 
45669 positive regulation of osteoblast differentiation 52 0.44 1.54 0.021 Up 
48546 digestive tract morphogenesis 17 0.57 1.51 0.021 Up 
51287 NAD binding 80 0.66 1.74 0.022 Up 
35255 ionotropic glutamate receptor binding 22 0.53 1.54 0.022 Up 
1501 skeletal system development 73 0.36 1.46 0.022 Up 
16581 NuRD complex 19 –0.47 –1.51 0.022 Down 
48812 neuron projection morphogenesis 39 0.40 1.34 0.022 Up 
8016 regulation of heart contraction 22 –0.42 –1.45 0.022 Down 
6096 glycolysis 77 0.67 1.73 0.022 Up 
51015 actin filament binding 68 –0.46 –1.68 0.022 Down 
  
71805 potassium ion transmembrane transport 18 –0.58 –1.59 0.022 Down 
42995 cell projection 68 0.36 1.39 0.022 Up 
8092 cytoskeletal protein binding 50 –0.41 –1.52 0.022 Down 
5506 iron ion binding 189 0.37 1.58 0.023 Up 
1836 release of cytochrome c from mitochondria 21 0.60 1.55 0.023 Up 
46933 hydrogen ion transporting ATP synthase activity, 
rotational mechanism 
16 0.60 1.63 0.023 Up 
3007 heart morphogenesis 37 –0.44 –1.56 0.023 Down 
6897 endocytosis 87 –0.38 –1.55 0.023 Down 
6099 tricarboxylic acid cycle 23 0.63 1.55 0.023 Up 
1078 RNA polymerase II core promoter proximal 
region sequence-specific DNA binding 
transcription factor activity involved in negative 
regulation of transcription 
30 –0.41 –1.41 0.023 Down 
21772 olfactory bulb development 16 –0.62 –1.74 0.024 Down 
70588 calcium ion transmembrane transport 50 –0.47 –1.71 0.024 Down 
6816 calcium ion transport 88 –0.42 –1.56 0.024 Down 
4190 aspartic-type endopeptidase activity 18 0.54 1.46 0.024 Up 
35023 regulation of Rho protein signal transduction 59 –0.49 –1.69 0.025 Down 
32874 positive regulation of stress-activated MAPK 
cascade 
18 –0.60 –1.76 0.026 Down 
16323 basolateral plasma membrane 154 –0.39 –1.57 0.026 Down 
3779 actin binding 220 –0.39 –1.52 0.028 Down 
1822 kidney development 116 0.30 1.32 0.036 Up 
43499 eukaryotic cell surface binding 26 0.55 1.69 0.036 Up 
10243 response to organic nitrogen 63 0.40 1.52 0.036 Up 
16787 hydrolase activity 122 0.41 1.68 0.037 Up 
14823 response to activity 48 0.40 1.46 0.037 Up 
46328 regulation of JNK cascade 17 –0.47 –1.48 0.037 Down 
30279 negative regulation of ossification 18 0.55 1.55 0.038 Up 
  
70371 ERK1 and ERK2 cascade 21 0.49 1.55 0.038 Up 
30100 regulation of endocytosis 20 0.48 1.45 0.038 Up 
1516 prostaglandin biosynthetic process 16 0.46 1.45 0.038 Up 
45454 cell redox homeostasis 52 0.41 1.49 0.039 Up 
55114 oxidation-reduction process 259 0.37 1.57 0.040 Up 
45987 positive regulation of smooth muscle contraction 18 0.53 1.52 0.040 Up 
45907 positive regulation of vasoconstriction 28 0.45 1.49 0.040 Up 
15459 potassium channel regulator activity 21 0.49 1.49 0.040 Up 
51219 phosphoprotein binding 41 –0.40 –1.53 0.040 Down 
6633 fatty acid biosynthetic process 42 –0.40 –1.46 0.040 Down 
1958 endochondral ossification 23 0.49 1.58 0.041 Up 
1974 blood vessel remodeling 35 0.45 1.48 0.041 Up 
4221 ubiquitin thiolesterase activity 64 –0.41 –1.54 0.041 Down 
5525 GTP binding 355 0.44 1.57 0.042 Up 
8307 structural constituent of muscle 18 –0.63 –1.66 0.042 Down 
60395 SMAD protein signal transduction 18 0.56 1.51 0.042 Up 
43484 regulation of RNA splicing 21 –0.47 –1.57 0.042 Down 
5070 SH3/SH2 adaptor activity 17 –0.56 –1.54 0.042 Down 
30286 dynein complex 22 –0.53 –1.55 0.042 Down 
30217 T cell differentiation 33 –0.43 –1.54 0.042 Down 
1656 metanephros development 33 0.40 1.38 0.042 Up 
60359 response to ammonium ion 35 0.85 1.68 0.043 Up 
1657 ureteric bud development 44 0.45 1.54 0.043 Up 
4365 glyceraldehyde-3-phosphate dehydrogenase 
(NAD+) (phosphorylating) activity 
34 0.84 1.63 0.043 Up 
71333 cellular response to glucose stimulus 30 0.42 1.46 0.043 Up 
51056 regulation of small GTPase mediated signal 
transduction 
59 –0.49 –1.61 0.043 Down 
32266 phosphatidylinositol-3-phosphate binding 17 –0.51 –1.60 0.043 Down 
30889 negative regulation of B cell proliferation 15 0.53 1.41 0.043 Up 
  
7257 activation of JUN kinase activity 25 –0.45 –1.52 0.043 Down 
51018 protein kinase A binding 16 –0.51 –1.42 0.043 Down 
15991 ATP hydrolysis coupled proton transport 34 0.48 1.61 0.043 Up 
50821 protein stabilization 99 0.56 1.63 0.043 Up 
31397 negative regulation of protein ubiquitination 24 0.53 1.51 0.043 Up 
2027 regulation of heart rate 20 –0.56 –1.57 0.043 Down 
32312 regulation of ARF GTPase activity 21 –0.49 –1.47 0.043 Down 
17048 Rho GTPase binding 24 –0.58 –1.71 0.044 Down 
42383 sarcolemma 81 –0.41 –1.55 0.044 Down 
71889 14-3-3 protein binding 17 –0.59 –1.58 0.044 Down 
7628 adult walking behaviour 34 –0.37 –1.38 0.044 Down 
35267 NuA4 histone acetyltransferase complex 16 –0.55 –1.70 0.045 Down 
30032 lamellipodium assembly 25 0.51 1.54 0.045 Up 
10039 response to iron ion 21 0.58 1.50 0.045 Up 
5543 phospholipid binding 284 –0.36 –1.52 0.045 Down 
4725 protein tyrosine phosphatase activity 96 –0.36 –1.46 0.045 Down 
45765 regulation of angiogenesis 17 0.60 1.45 0.047 Up 
31175 neuron projection development 105 –0.33 –1.37 0.047 Down 
6874 cellular calcium ion homeostasis 69 –0.38 –1.43 0.048 Down 
48037 cofactor binding 18 0.42 1.45 0.049 Up 
Legend: ES; enrichment score; NES, normalized enrichment score.
  
Table S10. Genes differentially expressed between Lcn2-knockout compared to wild-type 
mice identified by RNA-sequencing (n=3/group). Here shown only genes with false 
discovery rate (FDR) q<0.05. 
GeneID logFC P-value q-value 
Hspa1a –2.15 1.13E-10 1.00E-06 
Nr4a1 –2.53 1.52E-10 1.00E-06 
Hspa1b –2.50 2.35E-09 1.03E-05 
Zbtb16 2.93 7.95E-09 2.63E-05 
Hamp –4.70 1.78E-07 0.00047 
Hif3a 2.77 8.97E-07 0.0018 
Myl4 –4.09 9.52E-07 0.0018 
Adipoq –4.90 2.71E-06 0.0045 
Lcn2 –2.25 1.06E-05 0.0155 
Slc4a8 2.16 1.47E-05 0.0195 
Fkbp5 1.38 1.72E-05 0.0195 
Cfd –3.38 1.78E-05 0.0195 
Sln –4.29 2.50E-05 0.0255 
Pdk4 1.68 3.17E-05 0.0299 
Serpine1 1.11 4.53E-05 0.0399 
Map3k6 1.31 5.30E-05 0.0437 
*logFC: logarithmic fold change. 
 
  
Table S11. Gene set enrichment analysis with differentially expressed genes between Lcn2-knockout compared to wild-type mice. 
Category Term Count Total % Involved Genes Fold 
Enrichment 
P-Value 
KEGG_PATHWAY mmu04510: Focal adhesion 31 198 15.7 MYL7, XIAP, ACTG1, ARHGAP5, 
COL6A6, COMP, ITGB6, PPP1R12A, 
PDGFD, EGF, PIK3R1, FN1, 
COL4A4, COL4A2, COL4A1, FLT1, 
ROCK2, ITGA1, ITGA2, HGF, FLNB, 
COL5A1, KDR, LAMA2, LAMA3, 
LAMA5, ITGA8, PDGFRA, LAMC1, 
MYLK, ITGA2B 
4.36 7.98E-12 
KEGG_PATHWAY mmu04512: ECM-receptor 
interaction 
17 83 20.5 COL4A4, COL4A2, COL4A1, ITGA1, 
ITGA2, COL5A1, HMMR, LAMA2, 
LAMA3, COL6A6, LAMA5, COMP, 
ITGA8, ITGB6, LAMC1, ITGA2B, 
FN1 
5.70 2.45E-08 
KEGG_PATHWAY mmu05222: Small cell lung 
cancer 
14 85 16.5 COL4A4, COL4A2, COL4A1, XIAP, 
ITGA2, CCNE2, LAMA2, LAMA3, 
CDKN2B, LAMA5, LAMC1, PIK3R1, 
FN1, ITGA2B 
4.59 8.06E-06 
KEGG_PATHWAY mmu05200: Pathways in cancer 29 323 9.0 XIAP, FOXO1, FGF12, ZBTB16, 
CCNE2, CDKN2B, TPR, EGF, 
PIK3R1, FN1, APC, COL4A4, 
COL4A2, COL4A1, EPAS1, 
RUNX1T1, ITGA2, BRCA2, HGF, 
STAT1, CTNNA3, WNT2B, LAMA2, 
CBLC, LAMA3, LAMA5, PDGFRA, 
LAMC1, ITGA2B 
2.50 9.08E-06 
KEGG_PATHWAY mmu04810: Regulation of actin 
cytoskeleton 
20 217 9.2 MYL7, ROCK2, ITGAE, SSH2, ITGA1, 
ITGA2, FGF12, ACTG1, ITGA8, 
ITGB6, PPP1R12A, PDGFRA, 
2.57 2.44E-04 
  
PDGFD, EGF, DIAP2, PIK3R1, 
MYLK, ITGA2B, APC, FN1 
KEGG_PATHWAY mmu05412: Arrhythmogenic 
right ventricular 
cardiomyopathy (ARVC) 
11 75 14.7 LAMA2, ACTG1, DMD, ITGA8, 
ITGB6, CACNG6, ITGA1, ITGA2, 
RYR2, CTNNA3, ITGA2B 
4.08 2.96E-04 
KEGG_PATHWAY mmu05410: Hypertrophic 
cardiomyopathy (HCM) 
11 84 13.1 LAMA2, ACTG1, DMD, ITGA8, 
ITGB6, CACNG6, ITGA1, ITGA2, 
RYR2, TTN, ITGA2B 
3.65 7.46E-04 
KEGG_PATHWAY mmu05414: Dilated 
cardiomyopathy 
11 92 12.0 LAMA2, ACTG1, DMD, ITGA8, 
ITGB6, CACNG6, ITGA1, ITGA2, 
RYR2, TTN, ITGA2B 
3.33 0.001 
KEGG_PATHWAY mmu04540: Gap junction 9 86 10.5 PLCB4, MAP3K2, GUCY1A2, 
PDGFRA, PDGFD, PRKG1, EGF, 
ITPR1, ITPR2 
2.91 0.011 
KEGG_PATHWAY mmu04144: Endocytosis 15 202 7.4 FLT1, ERBB4, PSD3, ASAP1, 
HSPA1A, EEA1, HSPA1B, KDR, 
CBLC, RAB11FIP2, TFRC, HSPA2, 
PDGFRA, H2-T24, EGF, AGAP2 
2.07 0.013 
KEGG_PATHWAY mmu04270: Vascular smooth 
muscle contraction 
10 120 8.3 PLCB4, ROCK2, MYH11, PPP1R12A, 
GUCY1A2, ADRA1A, PRKG1, ITPR1, 
MYLK, ITPR2 
2.32 0.027 
Footnote: Count: number of genes from 721 differentially expressed genes (P<0.05) involved in that pathway; %: genes involved/total number 
of genes in pathway; P-value: modified Fisher exact P-value.
  
Table S12. Gene set enrichment analysis with the differentially expressed genes between cells transfected with Lcn2 or empty plasmid. 
Category Term Count Total % Involved genes Fold 
Enrichment 
P-Value 
KEGG_PATHWAY rno05222: Small cell lung cancer 10 83 12.0 E2F3, PTGS2, ITGA6, BCL2, BCL2L1, 
RB1, BIRC3, BIRC2, MYC, TRAF4 
4.46 3.43E-04 
KEGG_PATHWAY rno04510: Focal adhesion 13 195 6.7 CAV1, ROCK2, COL3A1, ITGA11, 
ITGB5, BIRC3, BIRC2, ITGA6, 
RASGRF1, BCL2, GSK3B, THBS2, 
MYLK 
2.47 0.006 
KEGG_PATHWAY rno04110: Cell cycle 10 126 7.9 E2F3, CCNH, PLK1, GSK3B, BUB1, 
CDC20, RB1, CDC25C, ABL1, MYC 
2.94 0.006 
KEGG_PATHWAY rno04142: Lysosome 9 117 7.7 TCIRG1, AP1S2, GUSB, HEXA, 
LGMN, CTSD, PPT1, FUCA1, MANBA 
2.85 0.013 
KEGG_PATHWAY rno05200: Pathways in cancer 15 317 4.7 E2F3, FGF7, PTGS2, BCL2L1, RB1, 
BIRC3, STAT1, BIRC2, FZD6, ITGA6, 
BCL2, GSK3B, ABL1, MYC, TRAF4 
1.75 0.04 
KEGG_PATHWAY rno00511: Other glycan 
degradation 
3 16 18.8 HEXA, FUCA1, MANBA 6.94 0.067 
KEGG_PATHWAY rno05410: Hypertrophic 
cardiomyopathy (HCM) 
6 84 7.1 ACTC1, ITGA6, ITGA11, ITGB5, 
CACNG1, TNNI3 
2.64 0.074 
KEGG_PATHWAY rno04114: Oocyte meiosis 7 111 6.3 REC8, SLK, PLK1, BUB1, CDC20, 
AURKA, CDC25C 
2.33 0.077 
KEGG_PATHWAY rno05414: Dilated 
cardiomyopathy 
6 90 6.7 ACTC1, ITGA6, ITGA11, ITGB5, 
CACNG1, TNNI3 
2.47 0.09 
Footnote: Count: number of genes from 529 differentially expressed genes (P<0.05) involved in that pathway; %: genes involved/total number 
of genes in pathway; P-value: modified Fisher exact P-value. 
 
 
  
 
 
Figure S1. Hierarchical clustering showing that neonatal hypertrophic heart rat (HHR) (blue) and normal heart rat (NHR) (orange) form distinct 
groups based on gene expression (genes with Bonferroni adjustment <0.05). Numbers on the right are probeset numbers. Red depicts genes up-
regulated and green those down-regulated.
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Figure S2. Over-expression of Lcn2 in vitro. Lcn2 was over-expressed in H9c2 cells with the 
use of a plasmid. A, Optimisation of the concentration of Lcn2 plasmid in vitro. B, There 
were higher Lcn2 mRNA in cells transfected with LCN2-plasmid. C, Over-expression of in 
cells Lcn2 visualised by immunofluorescence. D, There was no difference in apoptotic cells 
measured by flow cytometry in cells transfected with Lcn2 compared to those transfected 
with empty plasmid. *** indicates P<0.001. Error bars represent standard error of mean. 
  
 
  
Figure S3. Representative of confocal microscopy images after transfection with Lcn2 
plasmid, which provided results for Figure 4 in the main paper. A, Wheat-germ agglutinin 
(WGA, red) and DAPI (blue) staining, used to estimate cell size (400x magnification, scale 
bar = 60µm). B, Phospho-histone H3 (pH3, green) and DAPI (blue), used to estimate cell 
proliferation and arrest (200x magnification, scale bar = 100µm). 
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Figure S4. There was no difference in apoptotic cells measured by flow cytometry in cells 
transfected with Lcn2 compared to those transfected with empty plasmid, demonstrated by 
annexin V bound to apoptotic cells determined by flow cytometry. Data shown as number of 
cells as a percentage of the total number of cells. Error bars represent standard error of mean. 
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